

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



Coleman, MP; Forman, D; Bryant, H; Butler, J; Rachet, B; Maringe, C; Nur, U; Tracey, E; Coory, M; Hatcher, J; McGahan, CE; Turner, D; Marrett, L; Gjerstorff, ML; Johannesen, TB; Adolfsson, J; Lambe, M; Lawrence, G; Meehan, D; Morris, EJ; Middleton, R; Steward, J; Richards, MA; ICBP Module 1 Working Group (, inc; Walters, S;) (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. *Lancet*, 377 (9760). pp. 127-38. ISSN 0140-6736 DOI: 10.1016/S0140-6736(10)62231-3

Downloaded from: <http://researchonline.lshtm.ac.uk/1857/>

DOI: [10.1016/S0140-6736\(10\)62231-3](https://doi.org/10.1016/S0140-6736(10)62231-3)

Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

THE LANCET

Supplementary webappendix

This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. *Lancet* 2010; published online Dec 22. DOI:10.1016/S0140-6736(10)62231-3

Cancer survival in Australia, Canada, Denmark, Norway, Sweden and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data

Programme Board: Ole Andersen (National Board of Health, Health Planning Division, Copenhagen, Denmark); Heather Bryant (Canadian Partnership Against Cancer, Toronto ON, Canada); David Currow (Cancer Institute NSW, Sydney NSW, Australia); Anna Gavin (Northern Ireland Cancer Registry, Belfast, Northern Ireland, UK); Gunilla Gunnarsson (Swedish Association of Local Authorities and Regions, Stockholm, Sweden); Jane Hanson (Cancer Services Co-ordinating Group, Cardiff, Wales, UK); David Hill (Cancer Council Victoria, Melbourne VIC, Australia); Stein Kaasa (University Hospital of Trondheim, Trondheim, Norway); Lone de Neergaard (National Board of Health, Health Planning Division, Copenhagen, Denmark); Michael A Richards (National Cancer Action Team, Department of Health, London, UK; Chair); Terry Sullivan (Cancer Care Ontario, Toronto ON, Canada); **Module 1 leaders:** Jan Adolfsson (Karolinska University Hospital, Stockholm, Sweden); Heather Bryant (Canadian Partnership Against Cancer, Toronto ON, Canada); Michael Coory (Cancer Council Victoria, Melbourne VIC, Australia); David Forman (International Agency for Research on Cancer, Lyon, France; Chair); Marianne L Gjerstorff (Danish Cancer Registry, National Board of Health, Copenhagen, Denmark); Tom Borge Johannesen (Norwegian Cancer Registry, Oslo, Norway); Mats Lambe (Regional Oncological Centre, Uppsala University Hospital, Uppsala, and Karolinska Institutet, Stockholm, Sweden); David Meechan (Trent Cancer Registry, Sheffield, UK); Richard Middleton (Northern Ireland Cancer Registry, Belfast, Northern Ireland, UK); Janey Shin (Canadian Partnership Against Cancer, Toronto ON, Canada); John Steward (Welsh Cancer Intelligence and Surveillance Unit, Cardiff, Wales, UK); Elizabeth Tracey (Cancer Institute NSW, Sydney NSW, Australia); **Cancer registries:** Juanita Hatcher, Carol Russell (Alberta Health Services, Edmonton AB, Canada); Andy Coldman, Mark Elwood, David Levy, Colleen E McGahan (British Columbia Cancer Agency, Vancouver BC, Canada); Dhali Dhaliwal, Donna Turner (CancerCare Manitoba, Winnipeg MB, Canada); Loraine Marrett, John McLaughlin, Kamini Milnes, Diane Nishri, Michael Sherar (Cancer Care Ontario, Toronto ON, Canada); Gerda Engholm (Department of Cancer Prevention and Documentation, Danish Cancer Society, Copenhagen, Denmark); Eva Morris, James Thomas (Northern and Yorkshire Cancer Registration and Information Service, Leeds, UK); Karen Linklater (Thames Cancer Registry, London, UK); Rebecca Elleray, David Meechan, Andy Smith (Trent Cancer Registry); Gill Lawrence (West Midlands Cancer Intelligence Unit, Birmingham, UK); Finian Bannon, Colin Fox (Northern Ireland Cancer Registry, Belfast, Northern Ireland, UK); Ceri White (Welsh Cancer Intelligence and Surveillance Unit, Cardiff, Wales, UK); **Clinical Committee:** Jonas Bergh (Karolinska Institutet, Stockholm, Sweden); John Boyages (Westmead Breast Cancer Institute, Sydney NSW, Australia); Michel Boyer (Sydney Cancer Centre, Sydney NSW, Australia); John Butler (Department of Health, London, UK); Peter Clark (Clatterbridge Centre for Oncology, Liverpool, UK); Bill Evans (Juravinski Cancer Centre at Hamilton Health Sciences, Cancer Care Ontario, Toronto ON, Canada); Hilary Fielder (Velindre NHS Trust, Cardiff, Wales, UK); Tony Fields (Alberta Health Services, Edmonton AB, Canada); Paul Finan (Leeds Teaching Hospitals NHS Trust, Leeds, UK); Tommy Fornander (Södersjukhuset, Stockholm, Sweden); Neville Hacker (University of New South Wales and Royal Hospital for Women, Sydney NSW, Australia); Louise Hanna (Velindre NHS Trust, Cardiff, Wales, UK); Thomas Hogberg (Skåne University Hospital, Lund, Sweden); Charlotte Hosbond (National Board of Health, Copenhagen, Denmark); Karl Kölbeck (Karolinska University Hospital, Stockholm, Sweden); Martin Lee (University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK); Peter Barrett Lee (Velindre NHS Trust, Cardiff, Wales, UK); Jason Lester (Velindre NHS Trust, Cardiff, Wales, UK); Mark Levine (McMaster University, Hamilton ON, Canada); Gudrun Lindmark (Skåne University Hospital, Malmö-Lund, Sweden); Tim Maughan (Velindre NHS Trust, Cardiff, Wales, UK); Usha Menon (University College London, London, UK); Ian Money Penny (Cardiff & Vale NHS Trust, Cardiff, Wales, UK); Andy Nordin (East Kent University Hospitals, Canterbury, UK); Julietta Patnick (NHS Cancer Screening, Sheffield, UK); Mick Peake (NHS Cancer Improvement, National Cancer Intelligence Network, Department of Respiratory Medicine, Leicester, UK); Andrew Radcliffe (Llandough Hospital, Penarth, Wales, UK); Barry Rosen (University of Toronto, Toronto ON, Canada); Annika Sjövall (Karolinska University Hospital, Stockholm, Sweden); Allan Spigelman (University of New South Wales, Sydney NSW, Australia); Gunnar Wagenius (Uppsala University Hospital, Uppsala, Sweden); Fredrik Wärnberg (Uppsala University Hospital, Uppsala, Sweden); Michael Williams (Addenbrooke's, Cambridge, UK); Ian Williamson (Royal Gwent Hospital, Newport, Wales, UK); **Central Analytic Team (Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK):** Claudia Allemani (also Analytical Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), Michel P Coleman, Libby Ellis, Camille Maringe, Ula Nur, Manuela Quaresma, Bernard Rachet, Sarah Walters.

Correspondence

MP Coleman, Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.

T +44 20 7612 7849, F +44 20 7436 4230, michel.coleman@lshtm.ac.uk

Additional references

1. National Board of Health. National Cancer Plan II - Denmark. Copenhagen, Denmark, National Board of Health, 1 June 2005.
2. Cancer Working Group. Cancer Services - Investing for the Future (The Campbell Report). Belfast, Department of Health and Social Services, 1996.
3. Department of Health. The NHS Cancer Plan. London, Department of Health, 2000.
4. Department of Health. Cancer Reform Strategy. London, Department of Health, June 2007.
5. Cancer Services Co-ordinating Group. Designed to Tackle Cancer in Wales: A Welsh Assembly Government Policy Statement. Welsh Assembly Government, December 2006.
http://www.wales.nhs.uk/sites3/Documents/322/D2TC_Strategic_Framework_2008-11.pdf
6. Department of Human Services. Victoria's Cancer Action Plan 2008-2011. Melbourne, Victoria, Victorian Government Department of Human Services, 2008.
7. Anon. National Cancer Strategy 2006-2009. Oslo, Norway, Ministry of Health and Care Services, 2010.
http://www.regjeringen.no/upload/kilde/hod/anb/2006/0020/ddd/pdfv/296675-kreftstrategien_eng_25102006_kjb.pdf
8. Ekos Research Associates. Canadian Partnership Against Cancer Corporation: evaluation. Final report: executive summary. Ottawa ON, Health Canada, 6 May 2010. <http://www.partnershipagainstcancer.ca/wp-content/uploads/CPACC-Evaluation-Executive-Summary.pdf>
9. Commission of Inquiry on a National Cancer Strategy. A national cancer strategy for the future. Swedish Government Official Reports SOU 2009:11. Stockholm, Sweden, Swedish Government Inquiries, 2009.
<http://www.regeringen.se/content/1/c6/12/09/76/01389b21.pdf>

Webappendix tables and figures

Exclusion tables

Webtable 1: Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007), all 12 jurisdictions combined: **colorectal cancer** (1 page)

Webtable 2: Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007), all 12 jurisdictions combined: **lung cancer** (1 page)

Webtable 3: Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007), all 12 jurisdictions combined: **breast cancer (women)** (1 page)

Webtable 4: Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007), all 12 jurisdictions (except Swedish regions) combined: **ovarian cancer** (1 page)

Number of patients

Webtable 5: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: **colorectal cancer** (2 pages)

Webtable 6: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: **lung cancer** (2 pages)

Webtable 7: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, country and jurisdiction: **breast cancer (women)** (2 pages)

Webtable 8: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, country and jurisdiction: **ovarian cancer** (2 pages)

Age at diagnosis

Webtable 9: Mean age at diagnosis: cancer, jurisdiction and calendar period of diagnosis (1 page)

Second and higher-order primary

Webtable 10: Number and percentage of adults (15-99 years) diagnosed during 1995-2007 whose cancer was a second or higher-order primary: by cancer and jurisdiction (1 page)

Patients dying within a month

Webtable 11: Number and percentage of patients dying within a month of diagnosis, by period of diagnosis and jurisdiction (1 page)

Survival by age and calendar period of diagnosis

Webtable 12: Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, **cohort analysis for 1995-99** (2 pages)

Webtable 13: Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, **cohort analysis for 2000-02** (2 pages)

Webtable 14: Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, **period analysis for 2005-07** (2 pages)

Incidence and mortality

Webtable 15: Age-standardised (world) annual incidence and mortality rates per 100,000 in 2000, with mortality-incidence ratios: cancer and country (1 page)

Annex figures

Incidence and mortality trends

Incidence and mortality trends 1985-2005: three-year moving average world-standardised rates per 100,000 per year (1 page)

Notes: Incidence data for Canada exclude Quebec; colorectal cancer includes cancers of the anus and anal canal; lung cancer includes cancers of the trachea. Mortality data labelled UK are for England and Wales only

Webfigure 1 – Ovarian cancer, incidence

Webfigure 2 – Lung cancer, incidence, males

Webfigure 3 – Lung cancer, incidence, females

Webfigure 4 – Ovarian cancer, mortality

Webfigure 5 – Lung cancer, mortality, males

Webfigure 6 – Lung cancer, mortality, females

Available on request

Exclusion tables

Annex Table 1: Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007): by cancer and jurisdiction (47 pages)

Survival by age and calendar period of diagnosis

Annex Table 2: One-year, five-year and conditional five-year relative survival (%), with 95% confidence intervals (CI), for adults (15-99 years) diagnosed with cancer during 1995-99: by cancer, age, sex, country and jurisdiction (14 pages)

Annex Table 3: One-year, five-year and conditional five-year relative survival (%), with 95% confidence intervals (CI), for adults (15-99 years) diagnosed with cancer during 2000-02: by cancer, age, sex, country and jurisdiction (14 pages)

Annex Table 4: One-year, five-year and conditional five-year relative survival (%), with 95% confidence intervals (CI), for adults (15-99 years), period analysis for 2005-07: by cancer, age, sex, country and jurisdiction (14 pages)

Table 1: Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007), all 12 jurisdictions combined: colorectal cancer

	1995-96			1997-98			1999-2000			2001-02		
Total registered	109,281	108,046	100.0	117,134	115,752	100.0	122,127	120,631	100.0	122,529	120,970	100.0
Ineligible	Records	Patients	%	Records	Patients	%	Records	Patients	%	Records	Patients	%
Incomplete data	61	61	<0.1	37	37	<0.1	33	33	<0.1	12	12	<0.1
Not resident in England or Wales	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
In situ neoplasm	391	356	0.3	553	497	0.4	712	649	0.5	1,082	1,016	0.8
Benign or uncertain	3,125	2,477	2.3	3,898	3,160	2.7	4,706	3,902	3.2	4,274	3,429	2.8
Metastatic	50	50	<0.1	49	49	<0.1	62	62	<0.1	62	62	<0.1
Otherwise ineligible	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Lymphoma	23	22	<0.1	32	32	<0.1	25	25	<0.1	19	19	<0.1
Leukaemia or myeloma	7	7	<0.1	0	0	0.0	0	0	0.0	0	0	0.0
Total ineligible		2,973	2.8		3,775	3.3		4,671	3.9		4,538	3.8
Total eligible		105,073	100.0		111,977	100.0		115,960	100.0		116,432	100.0
Aged 100+	28	28	<0.1	38	38	<0.1	39	39	<0.1	39	39	<0.1
Vital status unknown	182	124	0.1	156	121	0.1	208	176	0.2	149	139	0.1
Sex not known	1	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Sex-site error	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Invalid dates	8	7	<0.1	9	8	<0.1	22	21	<0.1	37	35	<0.1
Death certificate only	3,797	3,772	3.6	3,727	3,692	3.3	2,986	2,960	2.6	2,220	2,209	1.9
Autopsy only	161	155	0.1	134	131	0.1	121	119	0.1	94	91	<0.1
Synchronous tumours	595	296	0.3	683	337	0.3	1,051	767	0.7	692	413	0.4
Multiple primary same site	544	142	0.1	837	365	0.3	967	473	0.4	1,087	573	0.5
Total exclusions		4,524	4.3		4,692	4.2		4,555	3.9		3,499	3.0
Patients available for analyses		100,549	95.7		107,285	95.8		111,405	96.1		112,933	97.0

	2003-04			2005-06			2007			1995-2007		
Total registered	126,967	125,035	100.0	133,227	131,144	100.0	68,301	67,483	100.0	799,566	789,061	100.0
Ineligible	Records	Patients	%	Records	Patients	%	Records	Patients	%	Records	Patients	%
Incomplete data	16	16	<0.1	10	10	<0.1	20	20	<0.1	189	189	<0.1
Not resident in England or Wales	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
In situ neoplasm	1,443	1,350	1.1	2,130	1,995	1.5	1,374	1,308	1.9	7,685	7,171	0.9
Benign or uncertain	4,566	3,511	2.8	4,919	3,803	2.9	2,199	1,896	2.8	27,687	22,178	2.8
Metastatic	26	26	<0.1	20	20	<0.1	3	3	<0.1	272	272	<0.1
Otherwise ineligible	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Lymphoma	25	23	<0.1	20	20	<0.1	4	4	<0.1	148	145	<0.1
Leukaemia or myeloma	1	1	<0.1	1	1	<0.1	0	0	0.0	9	9	<0.1
Total ineligible		4,927	3.9		5,849	4.5		3,231	4.8		29,964	3.8
Total eligible		120,108	100.0		125,295	100.0		64,252	100.0		759,097	100.0
Aged 100+	34	33	<0.1	40	39	<0.1	27	26	<0.1	245	242	<0.1
Vital status unknown	142	125	0.1	120	110	<0.1	60	40	<0.1	1,017	835	0.1
Sex not known	1	0	0.0	3	0	0.0	0	0	0.0	5	0	0.0
Sex-site error	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Invalid dates	38	36	<0.1	17	16	<0.1	198	194	0.3	329	317	<0.1
Death certificate only	2,284	2,265	1.9	2,288	2,264	1.8	1,114	1,107	1.7	18,416	18,269	2.4
Autopsy only	74	73	<0.1	63	63	<0.1	41	41	<0.1	688	673	<0.1
Synchronous tumours	732	411	0.3	806	461	0.4	425	243	0.4	4,984	2,928	0.4
Multiple primary same site	1,412	790	0.7	1,576	907	0.7	950	578	0.9	7,373	3,828	0.5
Total exclusions		3,733	3.1		3,860	3.1		2,229	3.5		27,092	3.6
Patients available for analyses		116,375	96.9		121,435	96.9		62,023	96.5		732,005	96.4

Table 2: Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007), all 12 jurisdictions combined: lung cancer

	1995-96			1997-98			1999-2000			2001-02		
Total registered	114,804	114,702	100.0	114,920	114,816	100.0	116,189	116,064	100.0	115,622	115,497	100.0
Ineligible	Records	Patients	%	Records	Patients	%	Records	Patients	%	Records	Patients	%
Incomplete data	71	71	<0.1	47	47	<0.1	28	28	<0.1	33	33	<0.1
Not resident in England or Wales	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
In situ neoplasm	20	17	<0.1	21	20	<0.1	23	21	<0.1	16	13	<0.1
Benign or uncertain	1,041	1,019	0.9	967	941	0.8	798	781	0.7	461	452	0.4
Metastatic	386	386	0.3	229	229	0.2	295	295	0.3	275	274	0.2
Otherwise ineligible	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Lymphoma	21	21	<0.1	14	14	<0.1	18	18	<0.1	17	17	<0.1
Leukaemia or myeloma	7	7	<0.1	1	1	<0.1	1	1	<0.1	5	5	<0.1
Total ineligible		1,521	1.3		1,252	1.1		1,144	1.0		794	0.7
Total eligible		113,181	100.0		113,564	100.0		114,920	100.0		114,703	100.0
Aged 100+	6	6	<0.1	8	8	<0.1	11	11	<0.1	12	11	<0.1
Vital status unknown	152	82	<0.1	144	97	<0.1	205	178	0.2	138	106	<0.1
Sex not known	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Sex-site error	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Invalid dates	18	14	<0.1	37	33	<0.1	14	13	<0.1	7	6	<0.1
Death certificate only	7,626	7,585	6.7	7,108	7,088	6.2	6,080	6,065	5.3	4,671	4,659	4.1
Autopsy only	391	386	0.3	328	320	0.3	248	246	0.2	243	240	0.2
Synchronous tumours	259	238	0.2	260	236	0.2	491	445	0.4	263	206	0.2
Multiple primary same site	63	12	<0.1	100	41	<0.1	162	88	<0.1	196	116	0.1
Total exclusions		8,323	7.4		7,823	6.9		7,046	6.1		5,344	4.7
Patients available for analyses		104,858	92.6		105,741	93.1		107,874	93.9		109,359	95.3

	2003-04			2005-06			2007			1995-2007		
Total registered	118,510	118,367	100.0	123,098	122,925	100.0	62,327	62,236	100.0	765,470	764,607	100.0
Ineligible	Records	Patients	%	Records	Patients	%	Records	Patients	%	Records	Patients	%
Incomplete data	9	9	<0.1	14	14	<0.1	7	7	<0.1	209	209	<0.1
Not resident in England or Wales	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
In situ neoplasm	20	20	<0.1	16	16	<0.1	7	6	<0.1	123	113	<0.1
Benign or uncertain	366	345	0.3	289	269	0.2	153	147	0.2	4,075	3,954	0.5
Metastatic	104	104	<0.1	96	93	<0.1	28	28	<0.1	1,413	1,409	0.2
Otherwise ineligible	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Lymphoma	18	17	<0.1	19	18	<0.1	9	8	<0.1	116	113	<0.1
Leukaemia or myeloma	1	1	<0.1	1	1	<0.1	1	1	<0.1	17	17	<0.1
Total ineligible		496	0.4		411	0.3		197	0.3		5,815	0.8
Total eligible		117,871	100.0		122,514	100.0		62,039	100.0		758,792	100.0
Aged 100+	14	14	<0.1	25	25	<0.1	7	5	<0.1	83	80	<0.1
Vital status unknown	102	94	<0.1	86	72	<0.1	23	16	<0.1	850	645	<0.1
Sex not known	0	0	0.0	1	0	0.0	0	0	0.0	1	0	0.0
Sex-site error	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Invalid dates	15	14	<0.1	13	8	<0.1	31	28	<0.1	135	116	<0.1
Death certificate only	5,280	5,264	4.5	5,091	5,063	4.1	2,844	2,837	4.6	38,700	38,561	5.1
Autopsy only	146	145	0.1	167	166	0.1	113	113	0.2	1,636	1,616	0.2
Synchronous tumours	234	190	0.2	281	221	0.2	147	108	0.2	1,935	1,644	0.2
Multiple primary same site	262	164	0.1	343	225	0.2	218	154	0.2	1,344	800	0.1
Total exclusions		5,885	5.0		5,780	4.7		3,261	5.3		43,462	5.7
Patients available for analyses		111,986	95.0		116,734	95.3		58,778	94.7		715,330	94.3

Table 3: Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007), all 12 jurisdictions combined: breast cancer (women)

	1995-96			1997-98			1999-2000			2001-02		
	Records	Patients	%	Records	Patients	%	Records	Patients	%	Records	Patients	%
Total registered	122,919	122,393	100.0	132,491	131,604	100.0	139,188	138,172	100.0	143,751	142,614	100.0
Ineligible												
Incomplete data	105	105	<0.1	69	68	<0.1	37	36	<0.1	14	14	<0.1
Not resident in England or Wales	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
In situ neoplasm	5,218	5,027	4.1	6,547	6,307	4.8	7,604	7,349	5.3	8,458	8,188	5.7
Benign or uncertain	358	342	0.3	405	389	0.3	297	280	0.2	313	279	0.2
Metastatic	21	21	<0.1	21	20	<0.1	30	30	<0.1	21	21	<0.1
Otherwise ineligible	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Lymphoma	15	15	<0.1	17	17	<0.1	18	18	<0.1	13	13	<0.1
Leukaemia or myeloma	1	1	<0.1	0	0	0.0	0	0	0.0	0	0	0.0
Total ineligible		5,511	4.5		6,801	5.2		7,713	5.6		8,515	6.0
Total eligible		116,882	100.0		124,803	100.0		130,459	100.0		134,099	100.0
Aged 100+	65	65	<0.1	56	56	<0.1	82	82	<0.1	77	76	<0.1
Vital status unknown	285	190	0.2	262	201	0.2	303	266	0.2	300	283	0.2
Sex not known	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Sex-site error	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Invalid dates	4	4	<0.1	9	7	<0.1	6	6	<0.1	35	34	<0.1
Death certificate only	2,673	2,627	2.2	2,863	2,817	2.3	2,299	2,256	1.7	1,716	1,684	1.3
Autopsy only	20	20	<0.1	20	19	<0.1	15	15	<0.1	9	9	<0.1
Synchronous tumours	673	539	0.5	920	577	0.5	1,489	1,057	0.8	1,140	697	0.5
Multiple primary same site	324	55	<0.1	878	414	0.3	1,358	834	0.6	1,761	1,153	0.9
Total exclusions		3,500	3.0		4,091	3.3		4,516	3.5		3,936	2.9
Patients available for analyses		113,382	97.0		120,712	96.7		125,943	96.5		130,163	97.1

	2003-04			2005-06			2007			1995-2007		
	Records	Patients	%	Records	Patients	%	Records	Patients	%	Records	Patients	%
Total registered	150,970	149,318	100.0	156,212	154,153	100.0	78,762	77,925	100.0	924,293	916,179	100.0
Ineligible												
Incomplete data	17	17	<0.1	14	14	<0.1	5	5	<0.1	261	259	<0.1
Not resident in England or Wales	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
In situ neoplasm	9,866	9,337	6.3	11,532	10,768	7.0	5,988	5,729	7.4	55,213	52,705	5.8
Benign or uncertain	301	261	0.2	349	311	0.2	202	187	0.2	2,225	2,049	0.2
Metastatic	10	10	<0.1	9	9	<0.1	2	1	<0.1	114	112	<0.1
Otherwise ineligible	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Lymphoma	12	11	<0.1	6	6	<0.1	3	2	<0.1	84	82	<0.1
Leukaemia or myeloma	0	0	0.0	0	0	0.0	0	0	0.0	1	1	<0.1
Total ineligible		9,636	6.5		11,108	7.2		5,924	7.6		55,208	6.0
Total eligible		139,682	100.0		143,045	100.0		72,001	100.0		860,971	100.0
Aged 100+	77	77	<0.1	92	91	<0.1	39	39	<0.1	488	486	<0.1
Vital status unknown	265	247	0.2	313	303	0.2	81	76	0.1	1,809	1,566	0.2
Sex not known	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Sex-site error	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Invalid dates	62	58	<0.1	20	18	<0.1	23	22	<0.1	159	149	<0.1
Death certificate only	1,523	1,485	1.1	1,188	1,151	0.8	591	572	0.8	12,853	12,592	1.5
Autopsy only	10	10	<0.1	11	11	<0.1	6	6	<0.1	91	90	<0.1
Synchronous tumours	1,493	932	0.7	1,544	860	0.6	724	412	0.6	7,983	5,074	0.6
Multiple primary same site	2,488	1,660	1.2	3,201	2,278	1.6	1,682	1,270	1.8	11,692	7,664	0.9
Total exclusions		4,469	3.2		4,712	3.3		2,397	3.3		27,621	3.2
Patients available for analyses		135,213	96.8		138,333	96.7		69,604	96.7		833,350	96.8

Table 4: Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007), all 12 jurisdictions (except Swedish regions) combined: ovarian cancer

	1995-96			1997-98			1999-2000			2001-02		
Total registered	20,194	20,134	100.0	21,193	21,150	100.0	21,172	21,124	100.0	21,778	21,713	100.0
Ineligible	Records	Patients	%	Records	Patients	%	Records	Patients	%	Records	Patients	%
Incomplete data	30	30	0.1	8	8	<0.1	5	5	<0.1	25	25	0.1
Not resident in England or Wales	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
In situ neoplasm	197	195	1.0	80	79	0.4	29	28	0.1	35	35	0.2
Benign or uncertain	1,586	1,562	7.8	1,729	1,713	8.1	1,658	1,633	7.7	1,626	1,569	7.2
Metastatic	110	110	0.5	48	48	0.2	91	91	0.4	60	60	0.3
Otherwise ineligible	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Lymphoma	1	1	<0.1	2	2	<0.1	0	0	0.0	0	0	0.0
Leukaemia or myeloma	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Total ineligible		1,898	9.4		1,850	8.7		1,757	8.3		1,689	7.8
Total eligible		18,236	100.0		19,300	100.0		19,367	100.0		20,024	100.0
Aged 100+	4	4	<0.1	0	0	0.0	7	7	<0.1	5	5	<0.1
Vital status unknown	45	18	<0.1	29	21	0.1	33	28	0.1	32	28	0.1
Sex not known	0	0	0.0	1	1	<0.1	0	0	0.0	0	0	0.0
Sex-site error	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Invalid dates	3	2	<0.1	3	3	<0.1	0	0	0.0	3	3	<0.1
Death certificate only	790	784	4.3	797	790	4.1	770	764	3.9	592	588	2.9
Autopsy only	29	29	0.2	16	16	<0.1	13	13	<0.1	12	12	<0.1
Synchronous tumours	45	23	0.1	40	25	0.1	59	45	0.2	48	29	0.1
Multiple primary same site	34	9	<0.1	34	16	<0.1	28	12	<0.1	35	15	<0.1
Total exclusions		869	4.8		872	4.5		869	4.5		680	3.4
Patients available for analyses		17,367	95.2		18,428	95.5		18,498	95.5		19,344	96.6

	2003-04			2005-06			2007			1995-2007		
Total registered	21,245	21,203	100.0	21,295	21,250	100.0	10,648	10,625	100.0	137,525	137,199	100.0
Ineligible	Records	Patients	%	Records	Patients	%	Records	Patients	%	Records	Patients	%
Incomplete data	9	9	<0.1	24	24	0.1	3	3	<0.1	104	104	<0.1
Not resident in England or Wales	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
In situ neoplasm	28	25	0.1	29	26	0.1	46	46	0.4	444	434	0.3
Benign or uncertain	1,529	1,501	7.1	1,593	1,577	7.4	868	854	8.0	10,589	10,409	7.6
Metastatic	29	29	0.1	19	19	<0.1	6	6	<0.1	363	363	0.3
Otherwise ineligible	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Lymphoma	4	4	<0.1	1	1	<0.1	0	0	0.0	8	8	<0.1
Leukaemia or myeloma	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Total ineligible		1,568	7.4		1,647	7.8		909	8.6		11,318	8.2
Total eligible		19,635	100.0		19,603	100.0		9,716	100.0		125,881	100.0
Aged 100+	8	8	<0.1	5	5	<0.1	5	5	<0.1	34	34	<0.1
Vital status unknown	26	26	0.1	54	32	0.2	11	9	<0.1	230	162	0.1
Sex not known	0	0	0.0	0	0	0.0	0	0	0.0	1	1	<0.1
Sex-site error	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Invalid dates	3	3	<0.1	2	2	<0.1	9	8	<0.1	23	21	<0.1
Death certificate only	523	519	2.6	474	470	2.4	268	266	2.7	4,214	4,181	3.3
Autopsy only	11	11	<0.1	18	18	<0.1	5	5	<0.1	104	104	<0.1
Synchronous tumours	53	37	0.2	50	34	0.2	20	14	0.1	315	207	0.2
Multiple primary same site	41	28	0.1	36	21	0.1	19	11	0.1	227	112	<0.1
Total exclusions		632	3.2		582	3.0		318	3.3		4,822	3.8
Patients available for analyses		19,003	96.8		19,021	97.0		9,398	96.7		121,059	96.2

Table 5: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: colorectal cancer

		1995-99						2000-02						2005-07 ^a					
		Men		Women		Persons		Men		Women		Persons		Men		Women		Persons	
		All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors
Australian registries	15-44	597	517	611	532	1,208	1,049	379	348	385	345	764	693	662	484	716	530	1,378	1,014
	45-54	1,720	1,469	1,349	1,155	3,069	2,624	1,118	980	904	793	2,022	1,773	1,774	1,306	1,547	1,131	3,321	2,437
	55-64	3,982	3,275	2,568	2,151	6,550	5,426	2,529	2,188	1,728	1,500	4,257	3,688	4,551	3,345	3,011	2,160	7,562	5,505
	65-74	6,346	4,932	4,415	3,560	10,761	8,492	3,953	3,249	2,709	2,191	6,662	5,440	6,592	4,624	4,452	3,112	11,044	7,736
	75-99	5,202	3,460	5,831	3,875	11,033	7,335	3,922	2,671	4,038	2,739	7,960	5,410	6,896	4,340	7,000	4,488	13,896	8,828
	Total	17,847	13,653	14,774	11,273	32,621	24,926	11,901	9,436	9,764	7,568	21,665	17,004	20,475	14,099	16,726	11,421	37,201	25,520
New South Wales	15-44	322	280	330	290	652	570	217	202	188	170	405	372	371	264	378	272	749	536
	45-54	1,022	868	779	653	1,801	1,521	603	528	516	457	1,119	985	1,027	751	850	626	1,877	1,377
	55-64	2,298	1,898	1,517	1,265	3,815	3,163	1,501	1,314	1,045	919	2,546	2,233	2,633	1,913	1,778	1,257	4,411	3,170
	65-74	3,561	2,799	2,416	1,960	5,977	4,759	2,209	1,826	1,520	1,232	3,729	3,058	3,773	2,636	2,536	1,776	6,309	4,412
	75-99	2,906	1,940	3,207	2,141	6,113	4,081	2,099	1,453	2,177	1,465	4,276	2,918	3,804	2,368	3,961	2,561	7,765	4,929
	Total	10,109	7,785	8,249	6,309	18,358	14,094	6,629	5,323	5,446	4,243	12,075	9,566	11,608	7,932	9,503	6,492	21,111	14,424
Victoria	15-44	275	237	281	242	556	479	162	146	197	175	359	321	291	220	338	258	629	478
	45-54	698	601	570	502	1,268	1,103	515	452	388	336	903	788	747	555	697	505	1,444	1,060
	55-64	1,684	1,377	1,051	886	2,735	2,263	1,028	874	683	581	1,711	1,455	1,918	1,432	1,233	903	3,151	2,335
	65-74	2,785	2,133	1,999	1,600	4,784	3,733	1,744	1,423	1,189	959	2,933	2,382	2,819	1,988	1,916	1,336	4,735	3,324
	75-99	2,296	1,520	2,624	1,734	4,920	3,254	1,823	1,218	1,861	1,274	3,684	2,492	3,092	1,972	3,039	1,927	6,131	3,899
	Total	7,738	5,868	6,525	4,964	14,263	10,832	5,272	4,113	4,318	3,325	9,590	7,438	8,867	6,167	7,223	4,929	16,090	11,096
Canadian registries	15-44	920	768	871	729	1,791	1,497	622	544	598	528	1,220	1,072	1,053	786	1,009	737	2,062	1,523
	45-54	2,368	1,993	1,942	1,637	4,310	3,630	1,745	1,506	1,422	1,249	3,167	2,755	3,289	2,358	2,536	1,855	5,825	4,213
	55-64	5,336	4,355	3,553	2,957	8,889	7,312	3,697	3,128	2,497	2,145	6,194	5,273	6,926	4,913	4,490	3,221	11,416	8,134
	65-74	8,912	6,912	6,323	4,978	15,235	11,890	5,832	4,656	3,971	3,253	9,803	7,909	9,504	6,726	6,512	4,601	16,016	11,327
	75-99	8,144	5,417	9,463	6,256	17,607	11,673	5,801	4,001	6,564	4,399	12,365	8,400	9,878	6,149	10,887	6,850	20,765	12,999
	Total	25,680	19,445	22,152	16,557	47,832	36,002	17,697	13,835	15,052	11,574	32,749	25,409	30,650	20,932	25,434	17,264	56,084	38,196
Alberta	15-44	120	99	113	90	233	189	93	74	78	72	171	146	168	126	132	89	300	215
	45-54	304	251	224	183	528	434	227	189	197	166	424	355	525	369	378	288	903	657
	55-64	689	549	403	324	1,092	873	480	408	333	281	813	689	880	624	561	392	1,441	1,016
	65-74	1,052	811	641	507	1,693	1,318	751	594	454	366	1,205	960	1,162	802	817	542	1,979	1,344
	75-99	1,036	653	1,079	701	2,115	1,354	694	455	720	468	1,414	923	1,289	797	1,280	803	2,569	1,600
	Total	3,201	2,363	2,460	1,805	5,661	4,168	2,245	1,720	1,782	1,353	4,027	3,073	4,024	2,718	3,168	2,114	7,192	4,832
British Columbia	15-44	163	137	161	140	324	277	104	94	131	116	235	210	178	135	179	140	357	275
	45-54	444	372	359	299	803	671	336	291	275	237	611	528	586	424	521	386	1,107	810
	55-64	1,015	837	687	582	1,702	1,419	693	590	491	421	1,184	1,011	1,358	956	894	656	2,252	1,612
	65-74	1,824	1,453	1,235	1,000	3,059	2,453	1,156	918	779	647	1,935	1,565	1,918	1,403	1,306	947	3,293	2,350
	75-99	1,874	1,273	1,974	1,355	3,848	2,628	1,349	957	1,445	998	2,794	1,955	2,241	1,437	2,272	1,424	4,513	2,861
	Total	5,320	4,072	4,416	3,376	9,736	7,448	3,638	2,850	3,121	2,419	6,759	5,269	6,350	4,355	5,172	3,553	11,522	7,908
Manitoba	15-44	71	63	44	36	115	99	44	35	36	30	80	65	61	46	69	50	130	96
	45-54	156	127	122	103	278	230	99	90	78	69	177	159	202	139	144	99	346	238
	55-64	333	283	221	191	554	474	227	175	143	118	370	293	434	295	257	178	691	473
	65-74	571	443	414	322	985	765	321	262	244	202	565	464	478	332	348	238	826	570
	75-99	602	401	720	474	1,322	875	433	293	470	317	903	610	636	397	749	466	1,385	863
	Total	1,733	1,317	1,521	1,126	3,254	2,443	1,124	855	971	736	2,095	1,591	1,811	1,209	1,567	1,031	3,378	2,240

Table 5: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: colorectal cancer

		1995-99						2000-02						2005-07 ^a					
		Men		Women		Persons		Men		Women		Persons		Men		Women		Persons	
		All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors
Ontario	15-44	566	469	553	463	1,119	932	381	341	353	310	734	651	646	479	629	458	1,275	937
	45-54	1,464	1,243	1,237	1,052	2,701	2,295	1,083	936	872	777	1,955	1,713	1,976	1,426	1,493	1,082	3,469	2,508
	55-64	3,299	2,686	2,242	1,860	5,541	4,546	2,297	1,955	1,530	1,325	3,827	3,280	4,254	3,038	2,778	1,995	7,032	5,033
	65-74	5,465	4,205	4,033	3,149	9,498	7,354	3,604	2,882	2,494	2,038	6,098	4,920	5,877	4,189	4,041	2,874	9,918	7,063
	75-99	4,632	3,090	5,690	3,726	10,322	6,816	3,325	2,296	3,929	2,616	7,254	4,912	5,712	3,518	6,586	4,157	12,298	7,675
	Total	15,426	11,693	13,755	10,250	29,181	21,943	10,690	8,410	9,178	7,066	19,868	15,476	18,465	12,650	15,527	10,566	33,992	23,216
Denmark	15-44	185	156	201	163	386	319	116	93	106	89	222	182	206	145	200	137	406	282
	45-54	693	520	615	497	1,308	1,017	448	369	372	321	820	690	747	505	649	489	1,396	994
	55-64	1,634	1,235	1,309	1,011	2,943	2,246	1,136	914	876	727	2,012	1,641	2,161	1,502	1,671	1,161	3,832	2,663
	65-74	2,571	1,740	2,347	1,679	4,918	3,419	1,725	1,225	1,372	967	3,097	2,192	3,127	2,087	2,319	1,566	5,446	3,653
	75-99	3,016	1,662	3,822	2,188	6,838	3,850	1,941	1,073	2,344	1,334	4,285	2,407	3,147	1,725	3,791	2,080	6,938	3,805
	Total	8,099	5,313	8,294	5,538	16,393	10,851	5,366	3,674	5,070	3,438	10,436	7,112	9,388	5,964	8,630	5,433	18,018	11,397
Norway	15-44	158	125	211	182	369	307	115	97	123	108	238	205	216	155	242	188	458	343
	45-54	540	440	564	480	1,104	920	333	265	355	305	688	570	598	448	563	416	1,161	864
	55-64	1,201	970	1,064	906	2,265	1,876	860	715	748	640	1,608	1,355	1,596	1,141	1,337	957	2,933	2,098
	65-74	2,382	1,828	2,017	1,593	4,399	3,421	1,413	1,068	1,164	938	2,577	2,006	2,265	1,545	1,965	1,390	4,230	2,935
	75-99	2,840	1,808	3,726	2,401	6,566	4,209	1,988	1,215	2,419	1,567	4,407	2,782	3,150	1,982	3,828	2,344	6,978	4,326
	Total	7,121	5,171	7,582	5,562	14,703	10,733	4,709	3,360	4,809	3,558	9,518	6,918	7,825	5,271	7,935	5,295	15,760	10,566
Swedish regions	15-44	82	70	72	63	154	133	74	63	66	61	140	124	129	94	107	79	236	173
	45-54	276	236	238	210	514	446	217	186	168	143	385	329	311	234	310	230	621	464
	55-64	623	514	494	402	1,117	916	567	495	429	363	996	858	1,024	741	849	621	1,873	1,362
	65-74	1,223	982	1,006	822	2,229	1,804	890	727	751	607	1,641	1,334	1,571	1,124	1,246	864	2,817	1,988
	75-99	1,595	1,102	1,773	1,265	3,368	2,367	1,250	871	1,374	987	2,624	1,858	2,111	1,384	2,292	1,506	4,403	2,890
	Total	3,799	2,904	3,583	2,762	7,382	5,666	2,998	2,342	2,788	2,161	5,786	4,503	5,146	3,577	4,804	3,300	9,950	6,877
UK-England	15-44	1,580	1,265	1,462	1,184	3,042	2,449	1,028	842	968	833	1,996	1,675	1,891	1,317	1,809	1,243	3,700	2,560
	45-54	5,274	4,165	4,100	3,310	9,374	7,475	3,077	2,449	2,485	2,074	5,562	4,523	4,959	3,522	3,919	2,761	8,878	6,283
	55-64	13,577	10,273	8,667	6,737	22,244	17,010	8,475	6,695	5,358	4,321	13,833	11,016	14,627	10,085	9,512	6,410	24,139	16,495
	65-74	24,147	16,619	17,343	12,099	41,490	28,718	14,424	10,411	9,741	7,056	24,165	17,467	23,409	15,191	15,335	10,065	38,744	25,256
	75-99	24,570	13,204	29,556	15,138	54,126	28,342	16,929	9,382	18,353	9,822	35,282	19,204	27,105	14,836	27,481	14,610	54,586	29,446
	Total	69,148	45,526	61,128	38,468	130,276	83,994	43,933	29,779	36,905	24,106	80,838	53,885	71,991	44,951	58,056	35,089	130,047	80,040
UK-Northern Ireland	15-44	73	62	69	56	142	118	34	30	39	35	73	65	81	43	59	33	140	76
	45-54	197	158	158	135	355	293	118	96	99	86	217	182	204	144	177	122	381	266
	55-64	437	356	382	306	819	662	323	261	233	197	556	458	557	378	345	225	902	603
	65-74	791	559	599	447	1,390	1,006	451	335	327	252	778	587	867	555	577	375	1,444	930
	75-99	759	425	965	549	1,724	974	445	251	521	321	966	572	828	448	845	440	1,673	888
	Total	2,257	1,560	2,173	1,493	4,430	3,053	1,371	973	1,219	891	2,590	1,864	2,537	1,568	2,003	1,195	4,540	2,763
UK-Wales	15-44	122	89	108	92	230	181	68	58	60	53	128	111	122	85	112	81	234	166
	45-54	386	310	276	218	662	528	230	186	170	139	400	325	330	223	284	190	614	413
	55-64	1,006	750	603	455	1,609	1,205	598	457	356	279	954	736	1,075	701	690	457	1,765	1,158
	65-74	1,822	1,190	1,191	825	3,013	2,015	1,063	749	642	474	1,705	1,223	1,697	1,093	1,033	645	2,730	1,738
	75-99	1,759	911	2,109	1,028	3,868	1,939	1,168	659	1,216	634	2,384	1,293	1,965	1,086	1,748	905	3,713	1,991
	Total	5,095	3,250	4,287	2,618	9,382	5,868	3,127	2,109	2,444	1,579	5,571	3,688	5,189	3,188	3,867	2,278	9,056	5,466

^a No. of patients included in the period analyses (see text and Figure 1) for 2005-07 are those who were diagnosed during 2005-07 and those who were diagnosed earlier but were alive on 1 January 2005

Table 6: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: lung cancer

		1995-99						2000-02						2005-07 ^a					
		Men		Women		Persons		Men		Women		Persons		Men		Women		Persons	
		All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-year survivors
Australian registries	15-44	232	119	218	127	450	246	136	68	141	84	277	152	213	115	222	126	435	241
	45-54	1,080	425	714	345	1,794	770	601	269	461	251	1,062	520	872	351	787	372	1,659	723
	55-64	3,076	1,242	1,408	649	4,484	1,891	1,854	756	1,033	514	2,887	1,270	2,610	1,144	1,780	867	4,390	2,011
	65-74	6,292	2,246	2,642	1,032	8,934	3,278	3,377	1,261	1,554	642	4,931	1,903	4,301	1,706	2,349	971	6,650	2,677
	75-99	4,777	1,189	2,388	636	7,165	1,825	3,271	947	1,878	531	5,149	1,478	4,998	1,425	2,969	881	7,967	2,306
	Total	15,457	5,221	7,370	2,789	22,827	8,010	9,239	3,301	5,067	2,022	14,306	5,323	12,994	4,741	8,107	3,217	21,101	7,958
New South Wales	15-44	140	68	138	79	278	147	78	43	88	54	166	97	114	58	127	68	241	126
	45-54	608	238	427	207	1,035	445	388	178	274	145	662	323	495	198	457	224	952	422
	55-64	1,790	711	805	369	2,595	1,080	1,067	427	584	294	1,651	721	1,522	675	1,076	545	2,598	1,220
	65-74	3,633	1,274	1,524	612	5,157	1,886	1,973	746	872	354	2,845	1,100	2,484	997	1,352	551	3,836	1,548
	75-99	2,740	688	1,267	350	4,007	1,038	1,878	526	1,026	307	2,904	833	2,809	763	1,677	487	4,486	1,250
	Total	8,911	2,979	4,161	1,617	13,072	4,596	5,384	1,920	2,844	1,154	8,228	3,074	7,424	2,691	4,689	1,875	12,113	4,566
Victoria	15-44	92	51	80	48	172	99	58	25	53	30	111	55	99	57	95	58	194	115
	45-54	472	187	287	138	759	325	213	91	187	106	400	197	377	153	330	148	707	301
	55-64	1,286	531	603	280	1,889	811	787	329	449	220	1,236	549	1,088	469	704	322	1,792	791
	65-74	2,659	972	1,118	420	3,777	1,392	1,404	515	682	288	2,086	803	1,817	709	997	420	2,814	1,129
	75-99	2,037	501	1,121	286	3,158	787	1,393	421	852	224	2,245	645	2,189	662	1,292	394	3,481	1,056
	Total	6,546	2,242	3,209	1,172	9,755	3,414	3,855	1,381	2,223	868	6,078	2,249	5,570	2,050	3,418	1,342	8,988	3,392
Canadian registries	15-44	629	273	745	366	1,374	639	369	178	476	254	845	432	398	205	544	329	942	534
	45-54	2,516	983	2,407	1,190	4,923	2,173	1,615	625	1,557	783	3,172	1,408	2,023	820	2,479	1,172	4,502	1,992
	55-64	6,872	2,691	4,958	2,318	11,830	5,009	4,008	1,523	3,268	1,601	7,276	3,124	5,671	2,257	5,269	2,399	10,940	4,656
	65-74	12,089	4,308	7,690	3,184	19,779	7,492	6,971	2,576	4,840	2,047	11,811	4,623	9,005	3,469	7,459	3,224	16,464	6,693
	75-99	9,081	2,477	6,329	1,991	15,410	4,468	6,061	1,692	4,991	1,547	11,052	3,239	8,982	2,588	7,848	2,700	16,830	5,288
	Total	31,187	10,732	22,129	9,049	53,316	19,781	19,024	6,594	15,132	6,232	34,156	12,826	26,079	9,339	23,599	9,824	49,678	19,163
Alberta	15-44	73	21	86	43	159	64	41	17	57	20	98	38	43	20	80	53	123	73
	45-54	306	97	307	150	613	247	205	57	183	83	388	140	276	108	335	136	611	244
	55-64	829	305	656	287	1,485	592	460	163	434	181	894	344	720	272	784	360	1,504	632
	65-74	1,444	463	880	320	2,324	783	840	280	615	245	1,455	525	1,152	415	954	407	2,106	822
	75-99	1,189	283	743	233	1,932	516	795	199	634	190	1,429	389	1,198	333	994	343	2,192	676
	Total	3,841	1,169	2,672	1,033	6,513	2,202	2,341	717	1,923	719	4,264	1,436	3,389	1,148	3,147	1,299	6,536	2,447
British Columbia	15-44	129	51	167	83	296	134	62	26	85	43	147	75	55	28	86	49	141	77
	45-54	487	175	530	241	1,017	416	285	97	353	171	638	268	380	149	506	248	886	397
	55-64	1,343	508	968	427	2,311	935	712	248	652	289	1,364	537	1,110	385	1,081	486	2,191	871
	65-74	2,382	841	1,609	634	3,991	1,475	1,354	491	961	387	2,315	878	1,779	658	1,615	680	3,394	1,338
	75-99	2,002	493	1,541	433	3,543	926	1,328	334	1,185	364	2,513	698	1,950	544	1,759	579	3,709	1,123
	Total	6,343	2,068	4,815	1,818	11,158	3,886	3,741	1,202	3,236	1,254	6,977	2,456	5,274	1,764	5,047	2,042	10,321	3,806
Manitoba	15-44	20	13	29	14	49	23	15	5	26	16	41	21	17	12	27	18	44	30
	45-54	129	48	140	65	269	113	80	21	87	51	167	79	133	47	145	74	278	121
	55-64	397	148	300	158	697	306	248	94	235	119	483	213	316	127	338	151	654	278
	65-74	664	245	457	199	1,121	444	377	149	289	144	666	293	580	203	454	213	1,034	416
	75-99	585	202	393	156	978	358	399	141	357	140	756	281	602	191	574	240	1,176	431
	Total	1,795	656	1,319	588	3,114	1,244	1,119	417	994	470	2,113	887	1,648	580	1,538	696	3,186	1,276

Table 6: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: lung cancer

		1995-99						2000-02						2005-07 ^a					
		Men		Women		Persons		Men		Women		Persons		Men		Women		Persons	
		All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors
Ontario	15-44	407	188	463	230	870	418	251	123	308	175	559	298	283	145	351	209	634	354
	45-54	1,594	663	1,430	734	3,024	1,397	1,045	443	934	478	1,979	921	1,234	516	1,493	714	2,727	1,230
	55-64	4,303	1,730	3,034	1,446	7,337	3,176	2,588	1,018	1,947	1,012	4,535	2,030	3,525	1,473	3,066	1,402	6,591	2,875
	65-74	7,599	2,759	4,744	2,031	12,343	4,790	4,400	1,656	2,975	1,271	7,375	2,927	5,494	2,193	4,436	1,924	9,930	4,117
	75-99	5,305	1,499	3,652	1,169	8,957	2,668	3,539	1,018	2,815	853	6,354	1,871	5,232	1,520	4,521	1,538	9,753	3,058
	Total	19,208	6,839	13,323	5,610	32,531	12,449	11,823	4,258	8,979	3,789	20,802	8,047	15,768	5,847	13,867	5,787	29,635	11,634
Denmark	15-44	177	61	186	74	363	135	113	48	100	55	213	103	111	51	145	58	256	109
	45-54	852	279	840	321	1,692	600	517	192	498	205	1,015	397	601	250	760	314	1,361	564
	55-64	2,262	656	1,773	613	4,035	1,269	1,414	478	1,150	468	2,564	946	2,123	740	1,908	784	4,031	1,524
	65-74	3,698	883	2,461	638	6,159	1,521	2,374	652	1,695	539	4,069	1,191	2,901	964	2,456	888	5,357	1,852
	75-99	2,645	412	1,590	243	4,235	655	1,811	333	1,300	254	3,111	587	2,438	505	1,976	441	4,414	946
	Total	9,634	2,291	6,850	1,889	16,484	4,180	6,229	1,703	4,743	1,521	10,972	3,224	8,174	2,510	7,245	2,485	15,419	4,995
Norway	15-44	120	67	100	45	220	112	56	62	118	62	118	70	34	82	45	152	79	
	45-54	602	248	437	173	1,039	421	338	118	283	137	621	255	392	165	368	173	760	338
	55-64	1,185	399	692	277	1,877	676	803	266	558	220	1,361	486	1,314	491	1,013	423	2,327	914
	65-74	2,366	661	1,143	371	3,509	1,032	1,314	395	769	262	2,083	657	1,693	637	1,177	460	2,870	1,097
	75-99	1,912	420	856	178	2,768	598	1,390	278	677	152	2,067	430	1,868	470	1,169	308	3,037	778
	Total	6,185	1,795	3,228	1,044	9,413	2,839	3,901	1,081	2,349	801	6,250	1,882	5,337	1,797	3,809	1,409	9,146	3,206
Swedish regions	15-44	40	55	26	95	43	18	24	42	24	42	24	47	22	49	27	96	49	
	45-54	265	107	320	144	585	251	126	49	169	76	295	125	154	69	212	105	366	174
	55-64	612	211	517	220	1,129	431	382	149	363	169	745	318	637	258	764	331	1,401	589
	65-74	1,191	400	668	287	1,859	687	589	204	408	156	997	360	934	366	775	319	1,709	685
	75-99	915	213	542	153	1,457	366	552	116	375	107	927	223	885	271	731	225	1,616	496
	Total	3,023	948	2,102	830	5,125	1,778	1,667	524	1,339	523	3,006	1,047	2,657	986	2,531	1,007	5,188	1,993
UK-England	15-44	1,046	354	877	343	1,923	697	602	244	550	245	1,152	489	776	298	784	354	1,560	652
	45-54	5,660	1,725	3,794	1,307	9,454	3,032	3,118	970	2,507	926	5,625	1,896	3,510	1,170	3,129	1,240	6,639	2,410
	55-64	16,687	4,550	8,635	2,654	25,322	7,204	9,931	3,020	5,870	1,997	15,801	5,017	12,701	4,138	9,230	3,279	21,931	7,417
	65-74	34,890	7,819	19,574	4,482	54,464	12,301	18,358	4,613	10,946	2,969	29,304	7,582	20,910	6,147	14,008	4,440	34,918	10,587
	75-99	32,544	4,871	19,472	3,002	52,016	7,873	20,647	3,596	14,216	2,595	34,863	6,191	25,202	5,012	19,276	4,027	44,478	9,039
	Total	90,827	19,319	52,352	11,788	143,179	31,107	52,656	12,443	34,089	8,732	86,745	21,175	63,099	16,765	46,427	13,340	109,526	30,105
UK-Northern Ireland	15-44	46	19	28	74	31	13	6	18	11	31	17	32	14	30	16	62	30	
	45-54	186	64	131	38	317	102	109	39	77	186	59	131	50	113	37	244	87	
	55-64	491	134	294	98	785	232	332	101	209	72	541	173	482	151	312	109	794	260
	65-74	1,079	264	598	162	1,677	426	597	158	354	71	951	229	744	201	460	145	1,204	346
	75-99	808	152	529	104	1,337	256	485	86	338	71	823	157	683	140	507	130	1,190	270
	Total	2,610	633	1,580	414	4,190	1,047	1,536	390	996	245	2,532	635	2,072	556	1,422	437	3,494	993
UK-Wales	15-44	49	18	60	28	109	46	33	14	29	62	26	56	22	46	20	102	42	
	45-54	340	99	276	99	616	198	204	59	165	71	369	130	238	75	244	105	482	180
	55-64	1,140	297	592	165	1,732	462	658	186	448	150	1,106	336	953	296	708	246	1,661	542
	65-74	2,372	477	1,345	270	3,717	747	1,265	293	792	198	2,057	491	1,513	430	1,003	295	2,516	725
	75-99	2,106	277	1,187	158	3,293	435	1,376	206	894	141	2,270	347	1,702	293	1,313	277	3,015	570
	Total	6,007	1,168	3,460	720	9,467	1,888	3,536	758	2,328	572	5,864	1,330	4,462	1,116	3,314	943	7,776	2,059

^a No. of patients included in the period analyses (see text and Figure 1) for 2005-07 are those who were diagnosed during 2005-07 and those who were diagnosed earlier but were alive on 1 January 2005

Table 7: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: breast cancer (women)

		1995-99		2000-02		2005-07 ^a	
		All	1-year survivors	All	1-year survivors	All	1-year survivors
Australian registries	15-44	4,297	4,229	2,845	2,807	4,929	3,961
	45-54	7,487	7,361	4,885	4,802	8,525	6,734
	55-64	6,901	6,692	5,069	4,954	9,427	7,327
	65-74	6,562	6,242	4,115	3,931	6,790	5,274
	75-99	5,507	4,712	3,670	3,184	6,317	4,679
	Total	30,754	29,236	20,584	19,678	35,988	27,975
New South Wales	15-44	2,437	2,395	1,630	1,606	2,779	2,254
	45-54	4,264	4,193	2,776	2,730	4,858	3,819
	55-64	3,979	3,871	2,961	2,898	5,575	4,354
	65-74	3,712	3,531	2,356	2,241	3,861	3,006
	75-99	3,111	2,662	2,145	1,883	3,663	2,704
	Total	17,503	16,652	11,868	11,358	20,736	16,137
Victoria	15-44	1,860	1,834	1,215	1,201	2,150	1,707
	45-54	3,223	3,168	2,109	2,072	3,667	2,915
	55-64	2,922	2,821	2,108	2,056	3,852	2,973
	65-74	2,850	2,711	1,759	1,690	2,929	2,268
	75-99	2,396	2,050	1,525	1,301	2,654	1,975
	Total	13,251	12,584	8,716	8,320	15,252	11,838
Canadian registries	15-44	7,442	7,261	4,524	4,438	8,056	6,418
	45-54	12,213	11,930	8,445	8,271	14,797	11,619
	55-64	11,814	11,442	8,214	7,984	15,643	12,057
	65-74	12,616	11,945	7,533	7,197	13,020	9,989
	75-99	11,365	9,894	7,387	6,408	13,240	9,714
	Total	55,450	52,472	36,103	34,298	64,756	49,797
Alberta	15-44	1,112	1,085	671	650	1,207	944
	45-54	1,670	1,633	1,265	1,237	2,222	1,736
	55-64	1,569	1,524	1,120	1,093	2,043	1,566
	65-74	1,536	1,440	997	956	1,762	1,384
	75-99	1,407	1,213	1,000	860	1,778	1,323
	Total	7,294	6,895	5,053	4,796	9,012	6,953
British Columbia	15-44	1,505	1,469	904	895	1,604	1,274
	45-54	2,577	2,517	1,792	1,755	2,994	2,390
	55-64	2,494	2,419	1,647	1,600	3,228	2,476
	65-74	2,730	2,606	1,508	1,448	2,663	2,022
	75-99	2,651	2,382	1,626	1,412	2,860	2,094
	Total	11,957	11,393	7,477	7,110	13,349	10,256
Manitoba	15-44	390	377	221	216	351	267
	45-54	692	678	443	435	790	613
	55-64	695	671	482	468	896	701
	65-74	756	711	392	370	706	550
	75-99	847	745	523	463	917	676
	Total	3,380	3,182	2,061	1,952	3,660	2,807
Ontario	15-44	4,435	4,330	2,728	2,677	4,894	3,933
	45-54	7,274	7,102	4,945	4,844	8,791	6,880
	55-64	7,056	6,828	4,965	4,823	9,476	7,314
	65-74	7,594	7,188	4,636	4,423	7,889	6,033
	75-99	6,460	5,554	4,238	3,673	7,685	5,621
	Total	32,819	31,002	21,512	20,440	38,735	29,781

Table 7: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: breast cancer (women)

		1995-99		2000-02		2005-07 ^a	
		All	1-year survivors	All	1-year survivors	All	1-year survivors
Denmark	15-44	1,788	1,744	1,126	1,104	1,945	1,566
	45-54	3,933	3,813	2,498	2,438	3,855	3,041
	55-64	4,129	3,913	3,062	2,918	5,694	4,420
	65-74	3,681	3,358	2,332	2,178	4,464	3,435
	75-99	3,783	3,029	2,588	2,111	4,389	3,120
	Total	17,314	15,857	11,606	10,749	20,347	15,582
Norway	15-44	1,323	1,280	828	810	1,498	1,174
	45-54	2,764	2,707	1,815	1,785	3,161	2,531
	55-64	2,437	2,350	2,162	2,116	3,896	3,075
	65-74	2,519	2,364	1,366	1,289	2,445	1,939
	75-99	2,994	2,538	1,858	1,573	3,121	2,304
	Total	12,037	11,239	8,029	7,573	14,121	11,023
Swedish regions	15-44	1,106	1,095	667	662	1,287	1,023
	45-54	2,843	2,809	1,622	1,614	2,569	2,077
	55-64	2,712	2,667	2,220	2,198	3,943	3,150
	65-74	2,452	2,368	1,535	1,497	2,766	2,137
	75-99	2,623	2,323	1,404	1,260	2,851	2,109
	Total	11,736	11,262	7,448	7,231	13,416	10,496
UK-England	15-44	17,899	17,277	11,476	11,164	20,545	16,368
	45-54	35,609	34,433	21,824	21,308	35,752	28,405
	55-64	34,083	32,375	24,064	23,181	45,629	35,979
	65-74	30,557	27,149	18,623	17,007	36,995	28,493
	75-99	37,373	28,012	24,124	18,767	41,505	28,907
	Total	155,521	139,246	100,111	91,427	180,426	138,152
UK-Northern Ireland	15-44	545	531	375	359	672	542
	45-54	1,061	1,031	623	594	1,148	883
	55-64	1,007	964	718	680	1,375	1,059
	65-74	838	766	502	471	950	722
	75-99	930	722	579	495	1,167	820
	Total	4,381	4,014	2,797	2,599	5,312	4,026
UK-Wales	15-44	992	955	631	609	1,075	858
	45-54	2,150	2,073	1,371	1,331	2,140	1,688
	55-64	2,074	1,969	1,566	1,478	3,050	2,414
	65-74	2,087	1,798	1,255	1,111	2,450	1,836
	75-99	2,597	1,864	1,606	1,182	2,731	1,878
	Total	9,900	8,659	6,429	5,711	11,446	8,674

^a No. of patients included in the period analyses (see text and Figure 1) for 2005-07 are those who were diagnosed during 2005-07 and those who were diagnosed earlier but were alive on 1 January 2005

Table 8: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: ovarian cancer

		1995-99		2000-02		2005-07 ^a	
		All	1-year survivors	All	1-year survivors	All	1-year survivors
Australian registries	15-44	377	347	212	194	414	303
	45-54	572	501	351	316	652	480
	55-64	685	564	435	367	800	588
	65-74	831	605	457	316	789	530
	75-99	891	367	615	273	884	402
	Total	3,356	2,384	2,070	1,466	3,539	2,303
New South Wales	15-44	222	205	121	111	223	159
	45-54	320	272	203	182	388	293
	55-64	391	323	252	217	463	338
	65-74	450	320	256	179	427	290
	75-99	497	212	339	159	512	232
	Total	1,880	1,332	1,171	848	2,013	1,312
Victoria	15-44	155	142	91	83	191	144
	45-54	252	229	148	134	264	187
	55-64	294	241	183	150	337	250
	65-74	381	285	201	137	362	240
	75-99	394	155	276	114	372	170
	Total	1,476	1,052	899	618	1,526	991
Canadian registries	15-44	963	883	614	575	1,085	827
	45-54	1,357	1,171	930	829	1,614	1,168
	55-64	1,472	1,202	1,097	902	1,931	1,386
	65-74	1,969	1,409	1,093	813	1,876	1,239
	75-99	1,716	830	1,256	613	1,807	846
	Total	7,477	5,495	4,990	3,732	8,313	5,466
Alberta	15-44	206	194	100	91	109	80
	45-54	186	163	101	91	206	154
	55-64	175	143	122	97	193	142
	65-74	204	141	106	82	168	109
	75-99	201	80	123	49	187	78
	Total	972	721	552	410	863	563
British Columbia	15-44	148	132	86	83	156	120
	45-54	256	221	164	147	272	208
	55-64	242	209	179	161	321	237
	65-74	357	261	168	130	311	210
	75-99	350	177	237	108	312	140
	Total	1,353	1,000	834	629	1,372	915
Manitoba	15-44	48	39	27	26	46	32
	45-54	56	51	44	35	87	59
	55-64	79	66	51	42	103	77
	65-74	97	73	75	56	94	62
	75-99	117	41	80	44	104	44
	Total	397	270	277	202	434	274
Ontario	15-44	561	518	401	376	774	595
	45-54	859	736	621	556	1,049	747
	55-64	976	784	745	602	1,314	930
	65-74	1,311	934	744	545	1,303	858
	75-99	1,048	532	816	412	1,204	584
	Total	4,755	3,504	3,327	2,491	5,644	3,714

Table 8: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: ovarian cancer

		1995-99		2000-02		2005-07 ^a	
		All	1-year survivors	All	1-year survivors	All	1-year survivors
Denmark	15-44	275	238	161	149	199	152
	45-54	568	487	317	268	431	336
	55-64	716	550	452	366	774	540
	65-74	807	491	511	341	709	449
	75-99	667	239	426	172	577	243
	Total	3,033	2,005	1,867	1,296	2,690	1,720
Norway	15-44	234	220	144	134	174	141
	45-54	449	398	253	226	374	277
	55-64	476	407	348	312	631	472
	65-74	583	400	324	247	442	297
	75-99	643	270	427	188	571	280
	Total	2,385	1,695	1,496	1,107	2,192	1,467
Swedish regions	15-44						
	45-54						
	55-64						
	65-74						
	75-99						
	Total						
UK-England	15-44	2,741	2,437	1,588	1,458	2,852	2,132
	45-54	4,375	3,554	2,508	2,085	3,646	2,624
	55-64	5,898	4,166	3,891	2,975	6,229	4,298
	65-74	6,739	3,828	4,059	2,453	5,838	3,519
	75-99	6,272	2,160	4,423	1,511	5,790	2,252
	Total	26,025	16,145	16,469	10,482	24,355	14,825
UK-Northern Ireland	15-44	115	107	81	76	120	106
	45-54	163	125	84	68	135	103
	55-64	203	150	116	92	215	138
	65-74	206	123	132	92	204	125
	75-99	159	61	123	38	151	60
	Total	846	566	536	366	825	532
UK-Wales	15-44	166	146	100	90	163	124
	45-54	305	227	168	146	243	173
	55-64	424	283	276	208	448	291
	65-74	534	279	305	152	429	253
	75-99	497	172	312	112	414	152
	Total	1,926	1,107	1,161	708	1,697	993

^a No. of patients included in the period analyses (see text and Figure 1) for 2005-07 are those who were diagnosed during 2005-07 and those who were diagnosed earlier but were alive on 1 January 2005

Table 9: Mean age at diagnosis (and standard deviation): cancer, jurisdiction and calendar period of diagnosis

	Calendar period					
	1995-1999		2000-2007		Overall	
	Mean	SD	Mean	SD	Mean	SD
Colorectal						
Alberta	69.6	12.7	69.0	13.0	69.2	12.9
British Columbia	70.5	12.1	70.4	12.6	70.4	12.4
Manitoba	70.5	12.4	70.5	13.0	70.5	12.8
Ontario	69.5	12.2	69.5	12.5	69.5	12.4
Denmark	71.1	11.8	70.9	11.7	71.0	11.8
Norway	71.7	11.7	71.8	12.3	71.8	12.1
Swedish regions	72.0	11.5	71.9	11.8	72.0	11.7
UK-England	71.4	11.8	71.7	12.0	71.6	11.9
UK-Northern Ireland	70.4	12.0	70.2	11.9	70.2	12.0
UK-Wales	71.3	11.7	71.5	11.7	71.4	11.7
New South Wales	68.9	12.2	69.6	12.3	69.4	12.3
Victoria	69.3	12.1	69.9	12.6	69.7	12.4
Overall	70.8	11.9	71.0	12.2	70.9	12.1
Lung						
Alberta	68.6	10.9	69.5	11.2	69.2	11.1
British Columbia	69.0	11.2	70.3	11.1	69.8	11.1
Manitoba	69.2	10.7	70.3	11.1	69.9	11.0
Ontario	68.3	10.8	69.2	11.1	68.9	11.0
Denmark	67.8	10.4	68.6	10.5	68.3	10.5
Norway	68.4	10.8	69.4	10.8	69.0	10.8
Swedish regions	68.1	10.5	68.9	10.6	68.6	10.6
UK-England	70.8	10.3	71.5	10.7	71.2	10.5
UK-Northern Ireland	69.8	10.3	70.0	10.4	69.9	10.4
UK-Wales	70.6	10.0	71.2	10.5	71.0	10.3
New South Wales	69.3	10.6	70.2	11.1	69.9	10.9
Victoria	69.8	10.5	70.7	11.1	70.4	10.9
Overall	69.9	10.5	70.6	10.8	70.3	10.7
Breast						
Alberta	60.9	14.5	61.1	14.3	61.0	14.4
British Columbia	62.3	14.3	62.1	14.2	62.2	14.3
Manitoba	63.4	14.5	63.5	14.5	63.4	14.5
Ontario	61.6	14.3	61.6	14.1	61.6	14.1
Denmark	62.6	14.0	63.1	13.8	62.9	13.9
Norway	63.2	14.6	62.4	14.3	62.7	14.4
Swedish regions	62.7	13.9	62.7	13.6	62.7	13.7
UK-England	62.8	14.8	63.1	14.6	63.0	14.7
UK-Northern Ireland	61.6	14.6	62.0	14.6	61.8	14.6
UK-Wales	63.9	14.7	64.0	14.3	63.9	14.5
New South Wales	60.6	14.0	60.7	13.9	60.6	14.0
Victoria	60.7	14.2	60.5	14.1	60.6	14.1
Overall	62.4	14.6	62.5	14.4	62.5	14.4
Ovary						
Alberta	59.7	16.7	62.0	15.7	61.1	16.1
British Columbia	63.9	15.3	63.9	15.4	63.9	15.3
Manitoba	64.9	15.7	64.7	15.4	64.8	15.5
Ontario	63.0	14.7	62.9	15.3	62.9	15.1
Denmark	63.4	13.7	64.6	13.5	64.2	13.6
Norway	64.3	14.4	65.0	14.6	64.7	14.6
Swedish regions	-	-	-	-	-	-
UK-England	63.7	14.8	64.6	15.0	64.3	14.9
UK-Northern Ireland	61.3	15.1	62.6	15.5	62.1	15.4
UK-Wales	64.9	14.1	65.4	14.4	65.2	14.3
New South Wales	63.4	15.4	63.9	15.6	63.7	15.5
Victoria	64.2	15.3	64.5	15.5	64.4	15.4
Overall	63.6	14.8	64.3	15.0	64.0	14.9

Swedish regions - no ovarian cancer data

Table 10: Number and percentage of adults (15-99 years) diagnosed during 1995-2007 whose cancer was a second or higher-order primary: by cancer and jurisdiction

	Colorectal cancer			Breast cancer		
	Second and higher-order primaries		All primaries	Second and higher-order primaries		All primaries
	No.	%		No.	%	
Alberta	2,240	13.0	17,263	1,848	8.7	21,255
British Columbia	4,161	14.6	28,418	3,241	9.9	32,648
Manitoba	1,319	14.8	8,918	995	11.0	9,061
Ontario	6,823	8.1	84,362	4,508	4.9	92,597
Denmark	3,658	7.9	46,183	2,689	5.5	49,001
Norway	4,920	12.0	40,909	2,808	8.3	34,001
Swedish regions	2,961	12.6	23,554	2,844	8.8	32,395
UK-England	21,820	6.2	352,801	18,198	4.2	435,247
UK-Northern Ireland	417	3.5	11,891	227	1.8	12,464
UK-Wales	1,955	7.9	24,882	1,277	4.6	27,828
New South Wales	3,311	6.3	52,303	1,154	2.3	49,832
Victoria	5,049	12.5	40,521	2,009	5.4	37,021
Overall	58,634	8.0	732,005	41,798	5.0	833,350

	Lung cancer			Ovarian cancer		
	Second and higher-order primaries		All primaries	Second and higher-order primaries		All primaries
	No.	%		No.	%	
Alberta	2,756	14.5	19,031	294	12.0	2,454
British Columbia	4,579	14.7	31,123	377	10.4	3,640
Manitoba	1,646	17.9	9,202	155	13.5	1,146
Ontario	7,793	8.7	89,963	1,182	8.5	13,970
Denmark	4,173	8.9	47,151	652	8.4	7,773
Norway	3,321	12.1	27,383	664	10.8	6,159
Swedish regions	1,769	12.1	14,605	-	-	-
UK-England	28,109	7.5	376,496	4,741	6.8	69,485
UK-Northern Ireland	462	4.1	11,356	144	6.3	2,296
UK-Wales	2,465	9.6	25,742	490	9.8	5,003
New South Wales	2,635	7.3	36,251	316	6.1	5,151
Victoria	3,772	14.0	27,027	422	10.6	3,982
Overall	63,480	8.9	715,330	9,437	7.8	121,059

Swedish regions - no ovarian cancer data

Table 11: Number and percentage of patients dying within a month of diagnosis, by period of diagnosis and

	1995-1999		2000-2007		Overall	
	No.	%	No.	%	No.	%
Colorectal						
Alberta	398	7.0	777	6.8	1,175	6.9
British Columbia	500	5.1	983	5.3	1,483	5.3
Manitoba	184	5.7	321	5.7	505	5.7
Ontario	2,732	9.4	4,388	8.0	7,120	8.5
Denmark ¹	-	-	1,252	8.1	1,252	8.1
Norway	746	5.1	1,517	5.8	2,263	5.6
Swedish regions	343	4.6	643	4.0	986	4.2
UK-England	16,383	12.6	22,111	10.0	38,494	11.0
UK-Northern Ireland	391	8.8	506	6.9	897	7.6
UK-Wales	1,173	12.5	1,521	9.9	2,694	10.9
New South Wales ²	-	-	-	-	-	-
Victoria	834	5.8	1,197	4.6	2,031	5.0
Overall	23,684	10.4	35,216	8.4	58,900	9.1
Overall excluding New South Wales and Denmark	23,684	10.4	33,964	8.5	57,648	9.2
Lung						
Alberta	1,246	19.1	2,406	19.4	3,652	19.3
British Columbia	1,834	16.4	3,124	15.8	4,958	16.0
Manitoba	410	13.2	896	14.9	1,306	14.3
Ontario	7,776	23.9	13,951	24.5	21,727	24.3
Denmark ¹	-	-	2,499	15.9	2,499	15.9
Norway	1,304	13.9	2,748	15.4	4,052	14.9
Swedish regions	828	16.2	1,046	11.1	1,874	12.8
UK-England	37,635	26.3	53,415	23.1	91,050	24.3
UK-Northern Ireland	904	21.6	1,457	20.5	2,361	20.9
UK-Wales	2,812	29.7	3,923	24.3	6,735	26.3
New South Wales ²	-	-	-	-	-	-
Victoria	1,409	14.4	2,472	14.5	3,881	14.5
Overall	56,158	24.0	87,937	21.4	144,095	22.4
Overall excluding New South Wales and Denmark	56,158	24.0	85,438	21.7	141,596	22.5
Breast						
Alberta	83	1.1	118	0.9	201	1.0
British Columbia	86	0.7	171	0.8	257	0.8
Manitoba	25	0.7	47	0.8	72	0.8
Ontario	565	1.7	883	1.5	1,448	1.6
Denmark ¹	-	-	156	1.0	156	1.0
Norway	90	0.7	180	0.8	270	0.8
Swedish regions	43	0.4	50	0.2	93	0.3
UK-England	5,279	3.4	5,686	2.1	10,965	2.5
UK-Northern Ireland	77	1.8	88	1.1	165	1.3
UK-Wales	424	4.3	491	2.8	915	3.3
New South Wales ²	-	-	-	-	-	-
Victoria	148	1.1	215	0.9	363	1.0
Overall	6,820	2.6	8,085	1.7	14,905	2.0
Overall excluding New South Wales and Denmark	6,820	2.6	7,929	1.7	14,749	2.0
Ovary						
Alberta	86	8.9	127	8.7	213	8.7
British Columbia	107	7.9	180	7.9	287	7.9
Manitoba	37	9.3	75	10.1	112	9.9
Ontario	497	10.5	892	9.8	1,389	10.0
Denmark ¹	-	-	156	6.9	156	6.9
Norway	139	5.8	246	6.6	385	6.3
Swedish regions	-	-	-	-	-	-
UK-England	3,275	12.6	5,142	11.9	8,417	12.2
UK-Northern Ireland	90	10.6	138	9.6	228	10.0
UK-Wales	246	12.8	394	12.9	640	12.9
New South Wales ²	-	-	-	-	-	-
Victoria	130	8.8	193	7.8	323	8.2
Overall	4,607	11.5	7,543	10.8	12,150	11.1
Overall excluding New South Wales and Denmark	4,607	11.5	7,387	11.0	11,994	11.2

¹ Full dates were only collected from 2004 onwards

² Full dates were not collected by this registry

³ Swedish regions - no ovarian cancer data

Table 12: Number of patients, age-standardised and age-specific relative survival estimates (%) at 1 and 5 years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, cohort analysis for 1995-99

	Australia			Canada					Denmark	Norway	Swedish regions	United Kingdom				
	Australian registries	New South Wales	Victoria	Canadian registries	Alberta	British Columbia	Manitoba	Ontario				UK registries	England	Northern Ireland	Wales	
Colorectal cancer (persons)																
One year	No. of patients	32,621	18,358	14,263	47,832	5,661	9,736	3,254	29,181	16,393	14,703	7,382	144,088	130,276	4,430	9,382
	Age-standardised	80.0	80.3	79.6	79.1	77.6	80.7	79.8	78.7	71.7	78.6	81.8	70.2	70.2	74.3	68.3
	15-44 years	87.0	87.6	86.3	83.7	81.3	85.6	86.2	83.4	82.8	83.3	86.4	80.6	80.6	83.2	78.8
	45-54 years	85.8	84.8	87.2	84.5	82.6	83.9	83.1	85.3	78.2	83.7	87.1	80.2	80.1	82.9	80.1
	55-64 years	83.6	83.7	83.4	83.1	80.8	84.2	86.4	82.9	77.3	83.6	82.7	77.4	77.3	81.8	75.7
	65-74 years	80.9	81.7	79.9	80.1	80.0	82.3	79.8	79.4	71.8	79.9	82.9	71.2	71.2	74.7	68.8
	75-99 years	72.1	72.6	71.4	71.5	69.7	73.9	71.7	70.9	62.0	70.2	76.6	57.0	57.0	62.2	54.6
Five years	Age-standardised	60.0	61.2	58.4	58.1	56.3	59.8	57.6	58.0	48.2	56.9	58.5	47.8	47.8	51.1	45.9
	15-44 years	66.2	69.2	62.6	60.8	58.5	60.2	67.5	60.8	58.0	58.4	60.6	56.4	56.6	55.3	54.2
	45-54 years	63.9	63.7	64.1	61.4	58.8	61.7	57.1	62.3	50.7	57.0	60.8	53.2	53.1	57.4	52.8
	55-64 years	62.4	63.2	61.3	59.6	58.5	59.5	58.6	59.9	49.9	62.1	60.3	52.4	52.3	56.2	51.7
	65-74 years	60.9	62.4	59.1	59.3	59.7	62.1	59.3	58.3	48.9	59.0	59.2	48.4	48.5	52.0	44.7
	75-99 years	53.9	55.5	52.1	53.9	49.4	56.9	52.8	53.8	42.7	50.2	55.0	39.2	39.2	42.6	37.6
Conditional 5-year	No. of patients	24,926	14,094	10,832	36,002	4,168	7,448	2,443	21,943	10,851	10,733	5,666	92,915	83,994	3,053	5,868
	Age-standardised	75.0	76.2	73.4	73.6	72.5	74.2	72.2	73.8	67.3	72.3	71.6	68.1	68.2	68.8	67.2
	15-44 years	76.1	79.1	72.6	72.6	71.9	70.3	78.3	72.9	70.1	70.1	70.2	70.0	70.2	66.5	68.8
	45-54 years	74.4	75.1	73.5	72.7	71.1	73.5	68.8	73.1	64.9	68.1	69.9	66.4	66.4	69.3	65.9
	55-64 years	74.6	75.5	73.4	71.7	72.4	70.6	67.8	72.3	64.5	74.3	72.9	67.7	67.7	68.7	68.3
	65-74 years	75.3	76.3	74.0	74.1	74.7	75.4	74.4	73.5	68.2	73.8	71.4	68.0	68.1	69.6	65.0
	75-99 years	74.8	76.3	72.9	75.3	70.9	76.9	73.6	75.8	68.8	71.6	71.8	68.8	68.8	68.6	68.8
Lung cancer (persons)																
One year	No. of patients	22,827	13,072	9,755	53,316	6,513	11,158	3,114	32,531	16,484	9,413	5,125	156,836	143,179	4,190	9,467
	Age-standardised	38.2	38.6	37.8	38.7	36.4	36.6	41.7	39.6	26.4	32.3	35.7	24.3	24.3	27.4	23.0
	15-44 years	55.1	53.5	57.7	46.7	41.1	45.5	47.4	48.0	37.1	51.0	45.5	36.7	36.2	42.2	42.5
	45-54 years	43.4	43.9	42.9	44.4	41.2	41.0	42.2	46.3	35.6	40.8	42.9	32.1	32.1	32.5	32.2
	55-64 years	43.1	42.9	43.4	42.9	41.1	40.8	44.3	43.7	31.8	36.2	38.3	28.6	28.6	30.0	26.9
	65-74 years	38.2	38.6	37.6	38.9	35.7	37.8	40.7	39.7	25.5	30.2	37.8	23.0	23.1	26.1	20.4
	75-99 years	28.2	29.5	26.7	31.1	30.3	27.9	39.2	31.4	16.7	23.3	26.3	16.0	16.1	20.9	13.9
Five years	Age-standardised	13.9	14.2	13.4	15.7	13.8	13.9	16.6	16.6	8.0	11.0	12.7	7.0	6.9	9.7	7.5
	15-44 years	28.6	26.3	32.2	23.8	21.4	21.8	29.3	24.6	19.7	27.5	17.2	18.0	17.4	27.4	22.5
	45-54 years	17.4	18.4	16.1	20.2	18.1	16.9	18.2	22.0	11.1	16.0	16.7	10.2	10.0	10.6	12.8
	55-64 years	15.9	16.0	15.8	18.1	17.2	16.6	19.3	18.7	9.9	12.4	14.4	8.7	8.7	9.7	8.9
	65-74 years	13.1	14.0	11.9	15.2	13.4	14.3	13.6	16.0	7.1	9.6	12.8	5.9	5.9	8.7	5.5
	75-99 years	8.0	8.4	7.4	10.4	7.9	8.2	13.9	11.4	3.4	5.2	8.5	2.9	2.8	5.9	2.5
Conditional 5-year	No. of patients	8,010	4,596	3,414	19,781	2,202	3,886	1,244	12,449	4,180	2,839	1,778	34,042	31,107	1,047	1,888
	Age-standardised	35.1	35.9	34.0	39.9	37.0	37.2	39.5	41.3	28.6	32.1	35.1	26.9	26.6	33.8	29.2
	15-44 years	51.9	49.2	55.9	51.0	52.0	48.0	61.8	51.2	53.2	53.9	37.8	48.9	47.9	65.0	52.9
	45-54 years	40.0	41.9	37.6	45.6	43.8	41.3	43.3	47.4	31.2	39.1	38.9	31.9	31.3	32.6	39.9
	55-64 years	36.9	37.3	36.4	42.3	41.8	40.7	43.4	42.7	31.2	34.2	37.4	30.5	30.2	32.4	33.0
	65-74 years	34.3	36.3	31.6	39.2	37.6	37.9	33.4	40.3	28.0	31.8	33.8	25.8	25.5	33.2	26.9
	75-99 years	28.3	28.6	27.8	33.6	26.2	29.4	35.6	36.3	20.3	22.5	32.3	17.9	17.5	28.5	18.3

Table 12: Number of patients, age-standardised and age-specific relative survival estimates (%) at 1 and 5 years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, cohort analysis for 1995-99

	Australia			Canada					Denmark	Norway	Swedish regions	United Kingdom				
	Australian registries	New South Wales	Victoria	Canadian registries	Alberta	British Columbia	Manitoba	Ontario				UK registries	England	Northern Ireland	Wales	
Breast cancer (women)																
One year	No. of patients	30,754	17,503	13,251	55,450	7,294	11,957	3,380	32,819	17,314	12,037	11,736	169,802	155,521	4,381	9,900
	Age-standardised	95.8	95.8	95.6	95.9	95.4	97.1	96.2	95.5	93.0	95.4	97.6	90.4	90.5	92.6	88.6
	15-44 years	98.5	98.4	98.7	97.7	97.7	97.7	96.7	97.7	97.7	96.8	99.1	96.6	96.6	97.5	96.4
	45-54 years	98.5	98.6	98.5	97.9	98.1	97.9	98.2	97.9	97.3	98.2	99.0	97.0	97.0	97.5	96.7
	55-64 years	97.5	97.9	97.1	97.5	97.8	97.6	97.2	97.4	95.7	97.0	98.9	95.7	95.7	96.6	95.7
	65-74 years	96.7	96.7	96.6	96.4	95.3	97.2	95.8	96.4	93.5	95.6	98.2	90.7	90.8	93.6	88.0
	75-99 years	91.6	91.6	91.7	93.0	92.0	96.0	94.8	91.6	87.6	92.6	95.1	81.6	81.7	85.3	78.4
Five years	Age-standardised	85.0	85.5	84.4	85.3	83.4	87.1	86.0	84.9	76.9	81.8	86.7	74.8	74.8	77.5	73.5
	15-44 years	84.3	84.6	83.9	82.4	82.9	80.7	79.7	83.0	79.5	80.5	83.9	78.3	78.3	79.7	77.8
	45-54 years	88.2	88.4	88.0	87.3	87.3	88.1	87.5	87.0	83.4	86.1	89.7	84.3	84.3	84.0	84.4
	55-64 years	88.4	89.0	87.5	87.1	87.0	87.2	85.9	87.2	80.9	85.6	90.6	83.1	83.1	83.4	83.1
	65-74 years	88.0	88.2	87.8	87.1	84.5	89.1	88.7	86.8	77.7	83.4	88.8	75.1	75.2	76.2	72.4
	75-99 years	78.3	79.0	77.3	81.9	77.9	86.1	84.2	80.7	69.7	75.6	81.0	63.0	62.9	70.8	61.5
Conditional 5-year	No. of patients	29,236	16,652	12,584	52,472	6,895	11,393	3,182	31,002	15,857	11,239	11,262	151,919	139,246	4,014	8,659
	Age-standardised	88.8	89.1	88.2	88.9	87.3	89.7	89.4	88.9	82.6	85.6	88.8	82.5	82.4	83.6	82.7
	15-44 years	85.6	86.0	85.0	84.3	84.9	82.6	82.4	85.0	81.4	83.1	84.6	81.0	81.0	81.8	80.8
	45-54 years	89.5	89.7	89.4	89.2	89.0	90.0	89.0	88.9	85.7	87.7	90.6	86.9	86.9	86.2	87.3
	55-64 years	90.6	90.9	90.2	89.4	89.0	89.3	88.4	89.6	84.5	88.2	91.6	86.8	86.8	86.3	86.9
	65-74 years	91.0	91.1	90.9	90.4	88.6	91.7	92.5	90.1	83.1	87.3	90.5	82.8	82.9	81.4	82.2
	75-99 years	85.4	86.2	84.3	88.1	84.7	89.7	88.8	88.1	79.6	81.6	85.2	77.2	77.0	83.0	78.4
Ovarian cancer																
One year	No. of patients	3,356	1,880	1,476	7,477	972	1,353	397	4,755	3,033	2,385	-	28,797	26,025	846	1,926
	Age-standardised	70.4	70.4	70.4	71.8	69.4	74.0	68.9	71.9	63.4	70.4	-	59.6	59.8	62.8	56.6
	15-44 years	92.1	92.4	91.7	91.8	94.3	89.3	81.2	92.4	86.6	94.1	-	89.1	89.0	93.1	88.0
	45-54 years	87.8	85.3	91.0	86.5	87.9	86.5	91.2	85.9	86.1	88.9	-	80.9	81.5	77.0	74.7
	55-64 years	82.9	83.2	82.4	82.2	82.4	87.0	84.1	80.9	77.6	86.1	-	71.0	71.2	74.5	67.3
	65-74 years	74.1	72.6	76.0	72.9	71.0	74.5	76.4	72.5	62.3	69.9	-	57.7	57.9	61.2	53.2
	75-99 years	44.4	46.5	41.7	51.4	43.9	54.3	37.1	53.4	38.4	45.0	-	36.6	36.5	41.8	36.5
Five years	Age-standardised	36.1	35.9	36.4	38.2	41.4	35.1	32.7	39.0	31.5	37.2	-	32.6	32.5	39.0	31.5
	15-44 years	73.0	71.0	75.9	74.0	84.5	65.9	56.4	73.7	62.3	72.6	-	73.0	73.0	73.5	72.1
	45-54 years	53.5	53.1	54.0	53.8	58.6	52.9	48.8	53.4	45.5	53.7	-	48.3	48.4	48.0	47.3
	55-64 years	43.3	42.1	44.8	43.9	44.7	46.0	41.8	43.4	36.9	46.8	-	36.5	36.5	41.7	33.0
	65-74 years	34.7	35.7	33.6	33.2	39.3	27.0	36.5	33.8	27.2	33.3	-	27.4	27.1	39.1	27.4
	75-99 years	15.8	15.8	15.7	23.5	23.4	19.8	9.1	26.4	18.4	18.1	-	18.4	18.3	24.5	17.9
Conditional 5-year	No. of patients	2,384	1,332	1,052	5,495	721	1,000	270	3,504	2,005	1,695	-	17,818	16,145	566	1,107
	Age-standardised	48.8	48.6	49.2	51.9	58.3	45.7	43.7	53.3	48.9	50.6	-	53.1	52.8	63.0	53.8
	15-44 years	79.3	76.9	82.7	80.6	89.7	73.9	69.5	79.7	71.9	77.2	-	81.9	82.1	79.0	81.9
	45-54 years	60.9	62.2	59.3	62.2	66.6	61.1	53.5	62.2	52.9	60.5	-	59.7	59.4	62.4	63.3
	55-64 years	52.2	50.6	54.4	53.4	54.3	52.8	49.7	53.6	47.6	54.3	-	51.4	51.3	56.0	49.1
	65-74 years	46.9	49.2	44.3	45.6	55.4	36.2	47.8	46.6	43.7	47.7	-	47.6	46.8	63.9	51.5
	75-99 years	35.5	33.9	37.7	45.7	53.4	36.4	24.6	49.5	48.0	40.2	-	50.3	50.0	64.2	49.1

Some age-standardised estimates arise from imputed age-specific estimates (see text)

Patients included in conditional five-year survival estimates are those who survived at least one year after diagnosis (see text)

Patients included in the period analysis are those who were diagnosed during 2005-07, or diagnosed earlier but alive on 1 January 2005 (see text and Figure 1 in *The Lancet* article)

Table 13: Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, cohort analysis for 2000-02

	Australia			Canada					Denmark	Norway	Swedish regions	United Kingdom				
	Australian registries	New South Wales	Victoria	Canadian registries	Alberta	British Columbia	Manitoba	Ontario				UK registries	England	Northern Ireland	Wales	
Colorectal cancer (persons)																
One year	No. of patients	21,665	12,075	9,590	32,749	4,027	6,759	2,095	19,868	10,436	9,518	5,786	88,999	80,838	2,590	5,571
	Age-standardised	82.5	83.2	81.6	81.5	79.8	82.4	80.4	81.7	73.9	78.7	82.8	73.0	72.9	76.8	72.3
	15-44 years	90.8	92.0	89.5	88.0	85.6	89.5	81.4	88.8	82.1	86.2	88.6	84.4	84.0	89.1	86.8
	45-54 years	87.9	88.3	87.5	87.3	84.1	86.7	90.1	87.9	84.5	83.2	85.7	81.7	81.6	84.3	81.6
	55-64 years	87.3	88.4	85.7	85.9	85.5	86.1	80.0	86.5	82.5	85.0	86.8	80.4	80.4	83.3	77.9
	65-74 years	83.5	83.9	82.9	82.6	81.5	82.8	84.1	82.6	72.9	79.7	83.1	74.3	74.2	77.7	73.6
	75-99 years	73.5	74.1	72.8	73.0	70.5	75.4	72.8	72.6	61.7	69.0	76.9	59.4	59.2	64.5	59.1
Five years	Age-standardised	63.4	65.1	61.1	60.9	58.0	61.5	59.6	61.3	51.7	58.8	60.6	51.3	51.2	54.3	50.3
	15-44 years	69.0	71.6	66.1	63.8	63.7	65.6	57.9	63.9	60.1	68.0	64.5	59.5	59.0	64.8	64.6
	45-54 years	66.6	68.6	64.1	63.8	59.8	62.6	68.1	64.6	57.3	62.5	59.5	56.3	56.4	58.4	54.4
	55-64 years	67.9	69.5	65.6	64.2	62.6	63.5	60.7	65.1	56.0	62.3	64.0	56.3	56.6	55.1	52.9
	65-74 years	64.9	67.0	62.2	62.4	62.4	62.5	63.8	62.1	50.5	58.8	60.2	52.5	52.5	55.1	51.7
	75-99 years	55.5	56.7	54.1	54.8	47.8	57.5	51.6	55.6	45.1	52.1	57.9	41.9	41.7	48.8	41.8
Conditional 5-year	No. of patients	17,004	9,566	7,438	25,409	3,073	5,269	1,591	15,476	7,112	6,918	4,503	59,437	53,885	1,864	3,688
	Age-standardised	76.7	78.2	74.9	74.7	72.5	74.8	74.0	75.2	70.1	74.7	73.3	70.3	70.3	71.1	69.7
	15-44 years	76.0	77.9	73.8	72.5	74.5	73.3	71.1	72.0	73.2	78.9	72.7	70.6	70.2	72.7	74.4
	45-54 years	75.7	77.7	73.3	73.1	71.1	72.2	75.6	73.5	67.8	75.1	69.4	68.9	69.1	69.3	66.7
	55-64 years	77.8	78.6	76.6	74.7	73.2	73.8	75.8	75.3	67.9	73.3	73.8	70.1	70.4	66.2	67.9
	65-74 years	77.7	79.8	75.1	75.5	76.5	75.5	75.9	75.2	69.2	73.8	72.5	70.7	70.7	70.9	70.2
	75-99 years	75.5	76.5	74.3	75.0	67.9	76.3	70.8	76.5	73.1	75.6	75.4	70.6	70.5	75.6	70.8
Lung cancer (persons)																
One year	No. of patients	14,306	8,228	6,078	34,156	4,264	6,977	2,113	20,802	10,972	6,250	3,006	95,141	86,745	2,532	5,864
	Age-standardised	40.9	41.5	39.9	39.7	36.3	37.5	44.1	40.5	31.3	32.2	36.6	27.5	27.5	28.3	25.9
	15-44 years	55.2	58.9	49.5	51.3	39.7	50.7	51.1	53.4	48.6	45.7	49.6	42.9	42.5	55.4	42.3
	45-54 years	49.6	49.8	49.2	44.6	37.5	42.1	47.4	46.7	39.3	41.1	42.5	33.8	33.8	31.8	35.3
	55-64 years	44.8	44.9	44.6	43.4	39.8	39.6	44.6	45.2	37.3	36.0	43.1	31.9	32.0	32.5	30.6
	65-74 years	40.0	40.6	39.3	40.1	38.1	38.7	45.1	40.5	30.1	32.3	36.8	26.2	26.4	24.8	24.3
	75-99 years	31.5	32.2	30.7	31.3	30.5	29.6	39.7	31.0	20.4	22.3	25.7	18.8	18.9	20.5	16.1
Five years	Age-standardised	15.1	16.2	13.6	15.9	13.1	14.0	19.4	16.7	9.6	11.0	11.6	8.1	8.0	9.7	7.6
	15-44 years	32.0	34.1	29.0	25.1	19.8	22.2	17.3	27.4	22.2	0.0	0.0	21.5	21.3	32.9	19.8
	45-54 years	19.8	21.3	17.4	20.2	17.1	18.0	19.4	21.6	13.1	17.0	14.4	10.3	10.2	11.0	11.2
	55-64 years	15.6	15.7	15.5	17.9	14.9	14.8	21.7	18.9	11.1	13.8	15.3	9.5	9.6	10.7	8.6
	65-74 years	14.2	15.6	12.4	15.4	12.7	14.6	21.0	15.7	8.8	10.8	10.8	7.1	7.1	7.8	6.3
	75-99 years	9.6	10.8	8.0	10.8	8.8	8.9	16.7	11.2	4.8	4.9	7.4	3.7	3.7	4.8	3.7
Conditional 5-year	No. of patients	5,323	3,074	2,249	12,826	1,436	2,456	887	8,047	3,224	1,882	1,047	23,140	21,175	635	1,330
	Age-standardised	36.0	38.1	33.0	39.4	35.6	36.5	44.2	40.5	29.4	32.8	31.5	27.6	27.4	31.8	27.7
	15-44 years	58.1	57.8	58.6	49.0	49.9	43.8	33.9	51.3	45.7	0.0	0.0	50.2	50.0	59.4	46.7
	45-54 years	40.0	42.8	35.5	45.2	45.7	42.6	40.9	46.3	33.4	41.4	33.8	30.4	30.2	34.5	31.7
	55-64 years	34.8	34.9	34.7	41.1	37.4	37.4	48.6	41.9	29.7	38.4	35.5	29.9	29.9	32.9	28.0
	65-74 years	35.5	38.5	31.5	38.4	33.3	37.9	46.6	38.8	29.1	33.5	29.4	27.1	27.0	31.5	26.0
	75-99 years	30.3	33.6	26.0	34.4	28.9	30.1	42.1	36.1	23.7	22.0	29.0	19.6	19.3	23.5	22.7

Table 13: Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, cohort analysis for 2000-02

	Australia			Canada					Denmark	Norway	Swedish regions	United Kingdom				
	Australian registries	New South Wales	Victoria	Canadian registries	Alberta	British Columbia	Manitoba	Ontario				UK registries	England	Northern Ireland	Wales	
Breast cancer (women)																
One year	No. of patients	20,584	11,868	8,716	36,103	5,053	7,477	2,061	21,512	11,606	8,029	7,448	109,337	100,111	2,797	6,429
	Age-standardised	96.3	96.5	96.0	96.2	95.9	96.5	96.4	96.0	94.3	95.8	98.4	92.4	92.5	95.0	89.8
	15-44 years	98.8	98.6	98.9	98.2	96.9	99.0	97.8	98.2	98.1	97.9	99.3	97.3	97.4	95.8	96.6
	45-54 years	98.5	98.5	98.5	98.2	98.0	98.2	98.4	98.2	98.0	98.6	99.7	97.8	97.9	95.6	97.4
	55-64 years	98.2	98.4	98.0	97.8	98.1	97.8	97.6	97.7	96.1	98.4	99.5	96.8	97.0	95.4	95.0
	65-74 years	96.9	96.5	97.4	97.1	97.2	97.7	96.0	97.0	95.6	95.9	99.1	93.0	93.1	95.8	90.3
	75-99 years	92.7	93.6	91.3	92.5	91.7	93.1	94.7	92.2	89.1	92.0	96.2	85.0	85.0	93.5	80.5
Five years	Age-standardised	87.0	87.4	86.5	86.4	84.9	87.5	83.9	86.6	81.5	83.8	89.3	78.8	78.8	81.6	76.7
	15-44 years	86.7	87.0	86.2	85.8	84.9	88.1	86.5	85.2	85.9	83.6	89.6	81.9	82.0	77.5	82.0
	45-54 years	89.3	89.7	88.9	88.8	86.6	90.0	90.5	88.9	87.0	90.7	92.7	87.2	87.4	79.9	86.4
	55-64 years	90.8	90.8	90.7	88.8	89.2	88.9	86.3	88.9	84.4	89.7	93.0	87.1	87.3	82.0	85.4
	65-74 years	89.2	89.5	88.9	89.2	88.3	89.8	83.7	89.7	83.0	85.2	93.1	79.5	79.6	80.6	77.8
	75-99 years	81.0	81.9	79.8	80.8	77.4	82.9	78.9	81.0	74.5	74.9	81.0	67.3	67.1	84.0	63.4
Conditional 5-year	No. of patients	19,678	11,358	8,320	34,298	4,796	7,110	1,952	20,440	10,749	7,573	7,231	99,737	91,427	2,599	5,711
	Age-standardised	90.3	90.6	90.0	89.8	88.5	90.6	87.0	90.2	86.4	87.3	90.6	85.0	85.0	86.3	85.1
	15-44 years	87.8	88.2	87.2	87.4	87.6	89.0	88.4	86.7	87.5	85.4	90.2	84.2	84.2	80.9	84.8
	45-54 years	90.7	91.0	90.3	90.5	88.3	91.7	92.0	90.5	88.8	92.0	93.0	89.1	89.3	83.6	88.8
	55-64 years	92.4	92.3	92.5	90.8	90.9	90.9	88.4	91.0	87.8	91.1	93.5	89.9	90.0	85.9	89.9
	65-74 years	92.1	92.7	91.2	91.8	90.8	92.0	87.2	92.5	86.8	88.8	94.0	85.4	85.4	84.1	86.2
	75-99 years	87.4	87.4	87.4	87.3	84.4	89.0	83.2	87.9	83.6	81.3	84.2	79.2	78.9	91.4	78.7
Ovarian cancer																
One year	No. of patients	2,070	1,171	899	4,990	552	834	277	3,327	1,867	1,496	-	18,166	16,469	536	1,161
	Age-standardised	71.1	72.8	68.9	73.3	71.0	75.3	74.1	73.1	67.9	74.3	-	62.4	62.6	64.9	60.0
	15-44 years	91.6	91.8	91.2	93.7	91.2	96.6	92.7	93.8	92.6	93.1	-	91.9	91.9	93.8	90.1
	45-54 years	90.2	89.9	90.7	89.4	90.3	89.8	79.8	89.7	84.8	89.6	-	83.5	83.4	81.2	87.1
	55-64 years	84.8	86.6	82.3	82.7	80.0	90.4	82.8	81.3	81.7	90.2	-	77.0	77.0	79.9	75.9
	65-74 years	70.4	71.5	69.1	75.6	78.6	78.6	75.8	74.4	68.4	77.6	-	61.1	61.5	71.0	50.8
	75-99 years	48.0	51.3	43.7	51.8	43.4	48.6	58.6	53.3	43.5	47.5	-	36.5	36.5	33.2	38.0
Five years	Age-standardised	37.1	39.6	34.1	38.4	34.9	37.8	37.1	39.1	33.7	40.2	-	34.3	34.3	37.8	33.8
	15-44 years	66.2	68.1	63.8	73.9	76.4	67.7	85.5	73.7	76.3	74.0	-	77.7	77.6	80.7	76.3
	45-54 years	57.1	59.9	53.2	57.3	62.0	59.4	50.9	56.3	54.0	56.2	-	51.4	51.3	46.9	55.0
	55-64 years	46.5	46.4	46.6	43.1	41.5	48.6	39.1	42.3	39.2	49.1	-	41.0	40.8	45.8	41.1
	65-74 years	31.3	34.8	26.9	34.2	28.8	28.4	36.9	36.1	28.2	38.6	-	28.9	28.8	41.4	24.1
	75-99 years	20.2	23.7	16.2	22.5	14.5	22.5	18.3	24.1	16.3	19.9	-	17.0	17.0	13.7	18.6
Conditional 5-year	No. of patients	1,466	848	618	3,732	410	629	202	2,491	1,296	1,107	-	11,556	10,482	366	708
	Age-standardised	50.4	53.0	47.0	50.9	46.4	49.1	48.1	52.2	47.2	52.2	-	52.8	52.6	55.0	53.9
	15-44 years	72.3	74.1	69.9	78.8	83.8	70.1	92.2	78.6	82.3	79.5	-	84.6	84.5	86.0	84.7
	45-54 years	63.3	66.7	58.6	64.1	68.6	66.1	63.8	62.8	63.6	62.8	-	61.6	61.6	57.8	63.2
	55-64 years	54.8	53.6	56.6	52.1	51.8	53.8	47.2	52.0	47.9	54.4	-	53.2	53.0	57.3	54.2
	65-74 years	44.5	48.7	39.0	45.3	36.7	36.1	48.7	48.5	41.3	49.8	-	47.3	46.8	58.3	47.5
	75-99 years	42.2	46.1	37.0	43.4	33.5	46.3	31.2	45.2	37.4	41.9	-	46.7	46.6	41.3	48.8

Some age-standardised estimates arise from imputed age-specific estimates (see text)

Patients included in conditional five-year survival estimates are those who survived at least one year after diagnosis (see text)

Patients included in the period analysis are those who were diagnosed during 2005-07, or diagnosed earlier but alive on 1 January 2005 (see text and Figure 1 in *The Lancet* article)

Table 14: Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, period analysis for 2005-07

	Australia			Canada					Denmark	Norway	Swedish regions	United Kingdom				
	Australian registries	New South Wales	Victoria	Canadian registries	Alberta	British Columbia	Manitoba	Ontario				UK registries	England	Northern Ireland	Wales	
Colorectal cancer (persons)																
One year	No. of patients	37,201	21,111	16,090	56,084	7,192	11,522	3,378	33,992	18,018	15,760	9,950	143,643	130,047	4,540	9,056
	Age-standardised	84.9	84.7	85.1	83.5	80.4	84.3	82.1	83.9	77.7	82.4	83.8	74.7	74.7	76.2	73.6
	15-44 years	89.5	87.1	92.2	92.1	90.2	91.7	90.9	92.8	87.9	89.3	85.1	82.6	82.5	82.6	84.2
	45-54 years	90.4	90.3	90.5	89.1	86.4	90.3	88.3	89.5	86.5	88.6	90.0	83.8	83.9	86.8	80.2
	55-64 years	89.5	89.0	90.3	87.9	84.9	88.6	87.6	88.4	83.6	86.6	86.7	81.5	81.6	82.3	79.6
	65-74 years	86.4	86.7	85.9	84.5	81.3	85.5	81.2	85.0	80.8	83.8	84.5	76.6	76.6	78.4	74.9
	75-99 years	76.4	76.5	76.3	74.5	71.2	75.5	73.8	74.9	63.7	73.3	77.9	61.8	61.8	63.3	62.1
Five years	Age-standardised	65.9	66.4	65.5	63.7	58.3	64.0	63.3	64.9	55.8	62.0	62.6	53.6	53.7	55.2	52.3
	15-44 years	71.2	69.4	73.4	68.8	64.3	68.3	74.1	69.2	62.3	69.6	66.0	59.3	59.1	59.0	62.8
	45-54 years	68.1	68.0	68.3	66.1	66.2	66.2	64.3	66.1	61.6	63.0	63.0	58.1	58.3	53.2	58.4
	55-64 years	68.5	67.2	70.4	67.4	61.1	67.3	67.3	68.8	57.8	63.5	66.2	58.3	58.6	56.7	53.9
	65-74 years	68.2	69.1	67.0	65.6	61.8	66.4	62.9	66.5	58.1	63.6	63.3	55.8	55.7	59.0	54.6
	75-99 years	59.5	61.5	57.0	56.7	47.8	56.9	57.4	58.7	47.9	57.1	58.3	44.5	44.4	50.1	43.8
Conditional 5-year	No. of patients	25,520	14,424	11,096	38,196	4,832	7,908	2,240	23,216	11,397	10,566	6,877	88,269	80,040	2,763	5,466
	Age-standardised	77.7	78.4	76.8	76.4	72.3	75.9	77.1	77.4	72.1	75.4	74.8	71.8	71.8	73.0	71.1
	15-44 years	79.6	79.6	79.6	74.6	71.2	74.5	81.5	74.6	70.9	77.9	77.5	71.8	71.6	71.4	74.6
	45-54 years	75.4	75.4	75.4	74.1	76.7	73.3	72.9	73.8	71.2	71.0	69.9	69.4	69.5	61.3	72.7
	55-64 years	76.5	75.5	78.0	76.7	72.0	76.0	76.8	77.8	69.1	73.3	76.4	71.5	71.9	68.9	67.6
	65-74 years	79.0	79.7	78.0	77.7	76.0	77.6	77.4	78.2	71.9	75.9	74.9	72.8	72.7	75.3	72.9
	75-99 years	77.8	80.4	74.6	76.1	67.2	75.3	77.8	78.4	75.2	77.9	74.8	72.0	71.9	79.2	70.5
Lung cancer (persons)																
One year	No. of patients	21,101	12,113	8,988	49,678	6,536	10,321	3,186	29,635	15,419	9,146	5,188	120,796	109,526	3,494	7,776
	Age-standardised	42.8	42.9	42.7	43.1	41.5	43.0	42.7	43.4	34.9	39.2	43.6	29.7	29.7	30.6	28.5
	15-44 years	62.2	61.1	63.7	58.0	59.6	61.7	61.6	56.6	41.6	54.0	64.1	43.6	43.8	45.2	38.3
	45-54 years	48.3	48.6	48.0	47.6	44.6	47.8	48.1	47.9	45.0	47.6	44.3	36.2	36.1	37.4	36.9
	55-64 years	49.7	50.3	48.7	46.8	44.1	46.1	45.4	47.6	40.4	44.0	46.4	34.4	34.5	33.9	32.7
	65-74 years	42.5	42.8	42.0	43.0	40.7	43.2	40.8	43.6	36.4	40.7	43.8	29.8	29.9	30.1	28.5
	75-99 years	30.8	30.4	31.3	34.7	34.7	33.9	35.7	34.7	23.4	26.9	35.8	19.7	19.7	22.1	19.3
Five years	Age-standardised	17.0	17.6	16.2	18.4	15.1	17.7	20.1	19.1	10.9	14.4	16.3	8.8	8.7	11.0	9.0
	15-44 years	34.1	32.4	36.3	31.8	27.1	30.4	20.4	33.6	19.2	35.1	38.1	20.4	20.1	30.5	18.1
	45-54 years	19.0	20.4	17.2	21.6	19.7	20.6	21.3	22.3	15.5	19.1	15.7	12.0	11.8	14.6	13.9
	55-64 years	20.2	20.6	19.7	20.8	17.9	20.4	23.8	21.2	12.6	16.2	16.9	10.4	10.3	12.0	11.1
	65-74 years	16.4	17.6	14.8	17.7	13.6	17.6	20.7	18.3	10.6	13.5	15.4	8.1	8.1	9.5	7.6
	75-99 years	10.0	10.4	9.5	12.8	9.5	11.4	16.0	13.6	5.9	7.1	11.8	4.1	4.1	5.4	4.5
Conditional 5-year	No. of patients	7,958	4,566	3,392	19,163	2,447	3,806	1,276	11,634	4,995	3,206	1,993	33,157	30,105	993	2,059
	Age-standardised	38.6	40.1	36.6	42.1	35.4	40.3	47.4	43.5	30.3	35.0	36.5	28.2	27.9	33.8	30.2
	15-44 years	54.9	53.1	57.0	54.7	45.5	49.3	33.1	59.3	46.2	64.9	59.4	46.8	45.9	67.5	47.3
	45-54 years	39.3	42.0	35.9	45.5	44.2	43.1	44.2	46.6	34.4	40.0	35.4	33.1	32.6	39.0	37.5
	55-64 years	40.7	41.0	40.5	44.4	40.5	44.2	52.6	44.5	31.1	36.7	36.4	30.3	29.9	35.3	33.8
	65-74 years	38.6	41.1	35.2	41.2	33.4	40.6	50.7	42.0	29.1	33.1	35.0	27.2	27.1	31.5	26.7
	75-99 years	32.6	34.4	30.4	36.8	27.5	33.6	44.9	39.0	25.3	26.4	33.0	21.1	20.8	24.5	23.6

Table 14: Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, period analysis for 2005-07

	Australia			Canada					Denmark	Norway	Swedish regions	United Kingdom				
	Australian registries	New South Wales	Victoria	Canadian registries	Alberta	British Columbia	Manitoba	Ontario				UK registries	England	Northern Ireland	Wales	
Breast cancer (women)																
One year	No. of patients	35,988	20,736	15,252	64,756	9,012	13,349	3,660	38,735	20,347	14,121	13,416	197,184	180,426	5,312	11,446
	Age-standardised	96.7	96.5	97.1	96.3	95.9	97.1	96.7	96.1	95.0	96.6	98.0	94.2	94.3	95.0	93.4
	15-44 years	98.7	98.6	98.7	98.5	98.1	98.8	96.6	98.6	99.1	98.1	99.4	98.2	98.2	97.7	97.9
	45-54 years	98.8	98.5	99.2	98.2	98.2	99.1	98.6	97.9	98.2	99.3	99.1	98.2	98.2	98.0	98.1
	55-64 years	98.7	98.6	98.7	97.7	97.4	98.0	97.3	97.7	97.9	98.5	99.1	97.5	97.5	98.7	97.4
	65-74 years	97.5	97.7	97.4	97.2	97.3	97.1	98.1	97.1	95.9	97.8	98.1	96.1	96.1	96.1	95.4
	75-99 years	93.1	92.2	94.3	93.1	91.7	95.1	94.2	92.6	89.5	92.3	96.3	87.2	87.2	89.2	85.0
Five years	Age-standardised	88.1	87.8	88.5	86.3	82.6	89.1	86.8	86.4	82.4	85.5	88.5	81.6	81.6	84.1	81.0
	15-44 years	87.9	87.9	87.9	87.0	89.2	87.3	83.5	86.5	87.4	85.1	91.4	84.1	84.1	83.4	83.9
	45-54 years	90.5	90.5	90.4	89.4	89.2	90.5	91.6	88.9	88.5	91.4	91.9	88.3	88.4	85.5	89.0
	55-64 years	91.5	92.0	90.8	89.0	88.0	89.9	88.4	89.0	86.6	91.6	92.1	88.8	88.8	87.3	88.9
	65-74 years	90.6	91.2	89.7	88.8	86.1	90.8	89.4	88.8	83.8	88.6	90.5	84.5	84.4	86.5	84.1
	75-99 years	82.1	79.9	84.9	80.3	70.3	86.7	81.9	80.7	73.9	75.1	81.4	69.8	69.6	78.7	67.5
Conditional 5-year	No. of patients	27,975	16,137	11,838	49,797	6,953	10,256	2,807	29,781	15,582	11,023	10,496	150,852	138,152	4,026	8,674
	Age-standardised	91.0	90.9	91.2	89.6	86.0	91.8	89.7	89.8	86.6	88.4	90.2	86.4	86.4	88.9	86.4
	15-44 years	89.1	89.1	89.1	88.3	90.9	88.4	86.4	87.8	88.2	86.7	91.9	85.6	85.6	85.3	85.7
	45-54 years	91.6	92.0	91.1	91.1	90.9	91.4	92.9	90.9	90.1	92.1	92.7	90.0	90.0	87.2	90.7
	55-64 years	92.7	93.2	92.0	91.1	90.4	91.8	90.9	91.1	88.5	92.9	93.0	91.0	91.1	88.5	91.2
	65-74 years	92.8	93.4	92.1	91.4	88.5	93.5	91.1	91.5	87.3	90.7	92.3	87.9	87.8	90.0	88.2
	75-99 years	88.2	86.6	90.3	86.2	76.7	91.2	86.9	87.1	82.6	81.3	84.5	80.1	79.8	89.8	79.4
Ovarian cancer																
One year	No. of patients	3,539	2,013	1,526	8,313	863	1,372	434	5,644	2,690	2,192	-	26,877	24,355	825	1,697
	Age-standardised	73.5	73.3	73.7	75.2	69.7	77.6	68.0	75.9	70.6	75.2	-	65.0	65.4	63.9	60.5
	15-44 years	91.8	92.1	91.3	92.6	86.0	94.0	90.0	93.3	92.0	92.5	-	93.0	93.0	97.3	90.0
	45-54 years	91.9	93.7	88.9	90.4	95.4	91.8	82.1	89.7	91.9	88.5	-	83.8	83.9	87.2	80.5
	55-64 years	86.7	87.5	85.6	84.9	83.0	88.2	79.1	84.7	80.6	89.8	-	79.1	79.8	71.3	73.9
	65-74 years	77.9	77.5	78.3	79.3	69.0	83.8	72.9	80.0	72.4	80.1	-	65.9	66.1	64.3	62.9
	75-99 years	46.6	44.9	49.1	52.8	45.4	53.1	43.1	54.8	46.7	49.0	-	38.5	38.9	39.9	32.2
Five years	Age-standardised	37.5	39.9	34.2	41.9	36.9	44.1	28.8	43.2	36.1	39.7	-	36.4	36.4	36.5	36.3
	15-44 years	69.8	72.8	66.1	75.8	65.6	74.4	72.1	77.8	72.9	76.1	-	79.4	79.1	86.3	80.2
	45-54 years	58.2	62.1	52.5	60.7	64.6	62.6	47.2	60.5	56.0	56.9	-	54.0	53.8	53.1	57.1
	55-64 years	41.8	42.1	41.1	47.3	42.0	47.8	31.1	49.3	40.4	46.9	-	42.2	42.2	34.3	45.5
	65-74 years	38.6	41.1	35.2	38.9	32.7	43.3	28.6	39.6	34.5	38.4	-	32.4	32.5	34.1	29.8
	75-99 years	16.6	19.8	12.3	24.7	18.7	26.8	9.2	26.6	17.1	19.4	-	18.0	18.0	21.7	16.4
Conditional 5-year	No. of patients	2,303	1,312	991	5,466	563	915	274	3,714	1,720	1,467	-	16,350	14,825	532	993
	Age-standardised	48.7	52.7	43.5	54.4	50.8	55.8	39.1	55.7	48.8	50.9	-	53.8	53.5	55.7	57.4
	15-44 years	76.0	79.1	72.3	81.9	76.3	79.2	80.1	83.4	79.3	82.2	-	85.4	85.0	88.7	89.1
	45-54 years	63.4	66.3	59.0	67.1	67.7	68.3	57.4	67.5	61.0	64.3	-	64.4	64.1	60.9	71.0
	55-64 years	48.1	48.1	48.0	55.6	50.7	54.2	39.3	58.2	50.1	52.2	-	53.3	53.0	48.2	61.6
	65-74 years	49.6	53.0	45.0	49.0	47.3	51.7	39.3	49.5	47.6	48.0	-	49.2	49.2	53.0	47.4
	75-99 years	35.7	44.1	25.1	46.8	41.2	50.5	21.3	48.6	36.6	39.7	-	46.7	46.3	54.3	51.0

Some age-standardised estimates arise from imputed age-specific estimates (see text)

Patients included in conditional five-year survival estimates are those who survived at least one year after diagnosis (see text)

Patients included in the period analysis are those who were diagnosed during 2005-07, or diagnosed earlier but alive on 1 January 2005 (see text and Figure 1 in *The Lancet* article)

Table 15: Age-standardised (world) annual incidence and mortality rates per 100,000 in 2000, with mortality-incidence ratios: cancer and country

	Colorectum	Lung			Breast	Ovary
	Persons	Males	Females	Persons	Females	
Incidence*						
Australia	40.3	38.2	17.5	27.0	84.4	8.0
Canada ¹	35.6	47.9	31.6	38.9	80.7	9.4
Denmark	33.9	46.2	31.6	37.9	83.7	13.2
Norway	36.1	35.5	19.2	26.4	71.0	12.8
Sweden	26.3	20.9	14.5	17.3	78.9	10.5
UK ²	29.3	43.8	22.6	31.9	82.1	11.9
Mortality						
Australia	14.2	32.1	13.6	22.1	16.6	4.8
Canada	12.2	44.5	24.8	33.5	18.3	5.4
Denmark	17.8	42.6	27.6	34.1	25.2	8.7
Norway	16.0	31.2	15.3	22.4	16.8	7.1
Sweden	11.5	21.0	13.4	16.7	15.8	6.7
UK ³	12.7	39.5	19.9	28.4	21.5	7.7
Mortality/Incidence ratios						
Australia	0.35	0.84	0.78	0.82	0.20	0.60
Canada ¹	0.34	0.93	0.78	0.86	0.23	0.57
Denmark	0.53	0.92	0.87	0.90	0.30	0.66
Norway	0.44	0.88	0.80	0.85	0.24	0.55
Sweden	0.44	1.00	0.92	0.97	0.20	0.64
UK	0.43	0.90	0.88	0.89	0.26	0.65

Source for incidence rates around 2000 (1998-2002): Cancer Incidence in Five Continents, vol IX¹²

Source for mortality rates for 2000: WHO mortality databank

¹ Excludes Quebec; ² England and Northern Ireland only; ³ England and Wales only

* Colorectal cancer includes cancers of the anus and anal canal; lung cancer includes cancers of the trachea.

